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ABSTRACT
DEVELOPMENT OF MACROMOLECULAR PRODRUG CONJUGATES FOR
THE DIAGNOSIS AND TREATMENT OF MUSCULOSKELETAL DISEASES

Macromolecular prodrug conjugate is a promising strategy for better diagnosis
and treatment of musculoskeletal diseases. Our lab has pioneered this effort and
has successfully developed multiple prodrug formulations. The general approach
we have taken is to incorporate active ingredient (AI, including imaging probe or
therapeutic agents) containing monomers into water-soluble and biocompatible
polymers, such as N-(2-Hydroxypropyl) methacrylamide (HPMA) copolymers.
Structural parameters of these polymeric prodrugs, such as molecular weight
(MW), drug loading, prodrug activation mechanism and the selection of drug payload may greatly affect therapeutic efficacy and the safety of the macromolecular
prodrugs. To investigate the impact of these structural parameters in my research,
(1) We have synthesized a series of the HPMA copolymer-based dexamethasone
prodrugs with different molecular weight and drug loading. After labeling with

125I

or fluorescent dye, these prodrugs were administered to a murine implant loosening model. The in vivo/ex vivo pharmacokinetics and biodistribution of these polymers and in vitro and in vivo cellular internalization were analyzed and compared.
(2) We designed and synthesized dexamethasone-containing monomers with different releasing chemistry and copolymerized with HPMA. The different in vitro
releasing rates of these prodrugs were confirmed. When evaluated in an adjuvant
induced arthritis rat model, these prodrugs demonstrated significantly different

xiv

therapeutic efficacy and duration. (3) To understand if the design principle we
learned from the dexamethasone prodrug can be extrapolated to other class of
drugs, we replaced dexamethasone with Tofacitinib (Tofa, a disease-modifying antirheumatic drug or DMARD) in the prodrug design. The resulting prodrug (P-Tofa)
was found to effectively ameliorate joint inflammation of the adjuvant-induced arthritis rat model. Collectively, the results from these systematic investigations provide us with more insight into the polymeric prodrug design principle and are
instructive for the future development and clinical translation of the macromolecular prodrugs for musculoskeletal and other relevant diseases.
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CHAPTER 1.

INTRODUCTION

1.1 Musculoskeletal Disorders
The musculoskeletal system is comprised of bones, muscles, cartilage, tendons, and ligaments, as well as joints, and other connective tissues [1]. In addition
to supporting the body, providing locomotion, the musculoskeletal system protects
the vital soft tissue organs in the body and harbors hematopoietic tissues (in the
bone marrow) and act as a reservoir for inorganic ions such as calcium and phosphorus [2]. The pathologic disorders of the musculoskeletal tissues affect large
population of people, resulting in acute or chronic pain, loss of body motion, reduction of the life quality and even mortality. The musculoskeletal diseases (MSD)
show highly related with age, body weight (obesity) and work type. Significant
economic burden has been reported to be associated with MSD, which affects
more than one out of every two persons in the United States age 18 and over, and
nearly three out of four age 65 and over [3]. The rate of chronic musculoskeletal
conditions found in the adult population is 76% greater than that of chronic circulatory diseases, which include coronary and heart conditions, and nearly twice that
of all chronic respiratory conditions [4]. The diseases of the musculoskeletal cover
a wide range of the pathological conditions, e.g., metabolic bone disorders (osteoporosis [5], Paget's disease [6], etc.); autoimmune diseases (rheumatoid arthritis,
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systemic lupus erythematosus, etc.); degenerative joint disease (osteoarthritis);
bone trauma or trauma-induced bone diseases (bone fracture, bone implant loosening, trauma-induced heterotopic ossification) and bone cancers (osteosarcoma,
bone metastasis), etc. In this chapter, we will provide an overview of several MSD
with high impact.
1.2 Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, inflammatory disorder that affects 0.8
percent of adults worldwide and around 1 percent of adults in the United States [7,
8]. The disease often leads to crippling pain associated with progressive articular
cartilage damage and peri-articular bone erosion. At present, there is no cure for
RA [9, 10].
Multiple classes of medications have been developed for the treatment of RA
patients. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, aspirin, ketoprofen and naproxen have been shown to ease pain and inflammation
associated with RA [11, 12] but they do not prevent joint damage and are often
associated with significant gastrointestinal, renal [13] and cardiovascular side effects [14]. Glucocorticoids (GC) have been widely used to treat RA patients [13].
Their long-term use, however, has been associated with serious side effects including bone loss with increased incidence of fractures, infections, hypertension
and cardiovascular complications, and diabetes mellitus [15, 16]. Disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX), sulfasalazine and leflunomide are currently being utilized to inhibit joint inflammation and
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have been shown to impede joint destruction [17]. Multiple biological DMARDs,
which selectively target proinflammatory cytokines or immunomodulatory pathways, have also been developed and shown to be clinically effective in suppressing joint inflammation and attenuating joint destruction [18]. The identification of
the key role of intracellular kinase signaling pathways in the regulation of proinflammatory cytokines and immune cell activation has led to the recent development of orally available low molecular weight drugs that selectively target individual
members of the Janus kinase pathway [19]. As an emerging class of medications,
Janus kinase inhibitors (JAK inhibitors) offer new hope to RA patients who have
experienced severe side effects or are refractory to current treatments [20].
1.3 Particle-induced implant loosening
Total joint replacement is considered as an excellent surgery for improving the
life quality for the patients who are suffering the end-stage of some musculoskeletal disorders, especially joint diseases such as osteoarthritis, inflammatory rheumatoid arthritis or the traumatic bone injury.

In 2011, 711,398 total knee

replacements and 464,452 total hip replacements were performed. The total cost
was over 19 billion dollars [21]. 10-20% of replaced joints, however, need to be
revised within 10-20 years after arthroplasty due to the osteoclast-mediated periimplant osteolysis at the interface between bone and implant [22].
The aseptic implant loosening is considered as one of the main causation of
the implant failure [23, 24], which is mainly induced by the granulomatous inflammatory reaction triggered by the wear-particle-activated macrophages [25-29].
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Macrophages release prostaglandins, cytokines, metalloproteinases and lysosomal enzymes (e.g. TNF-α, IL-1β, IL-6, and PGE-2) upon activation which initiate
the bone resorbing pathways cascades [30, 31].
Commonly used imaging tools such as x-ray, computerized tomography (CT)
and MRI in clinic have been used in the diagnosis of established bone loss of osteolysis and implant loosening. These methods are very effective in detecting osteolysis and associated loss of implant fixation.

However, they only reveal

anatomical changes within the limit of their imaging resolution, meaning when definitive evidence of osteolysis is detected, considerable bone loss has already occurred. To better prevent the osteolysis, there is a critical need for a theranostic
system that could both detect early wear particle-induced inflammatory events and
in addition therapeutically target the inflammatory process and prevent incipient
osteolysis. Intervention at the early stage of inflammation would definitely prolong
the life-time of the implant and improve long-term patient life quality.
1.4 Heterotopic ossification
Though genetic mutation causing heterotopic ossification (HO) is rare with a
prevalence around one of two million [32-35], HO is a common occurrence after
multiple forms of extensive trauma, including arthroplasty [36-39], traumatic burn
injury [40-43], and central nervous system (CNS) injury [44-47]. It has been reported that the incidence rate of tHO is 10-20% in patients receiving arthroplasty
[36], 0.1-3.3% in postburn patients [41], and 20%–30% in spinal cord injured patients [48]. The occurrence rate increases to as high as 63% following combatrelated amputation [49] and 60.1% in patients undergoing limb salvage [50]. The
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cost of the treatment and prophylaxis of tHO varies depending on the severity,
cause, and therapeutic methods [51-53]. tHO does not only induce severe permanent pain [33], joint spasticity and autonomic dysreflexia [54, 55], but also causes
increased pressure to the tissue under the tHO site leading to blood clot and deep
vein thrombosis which affects blood circulation, possibly resulting in fatality [56].
tHO is a complex process that involves trauma, injury, and stimulations inducing the activation of the inflammation cascade and differentiation of stem cells into
chondrocytes and osteoblasts. Severe systemic and stimulation-specific inflammation evident by immediate elevated levels of inflammatory cytokines and elevated injury severity score is associated with the development of tHO [57]. No
single simple mechanism currently exists, although many common cellular mechanisms have been investigated within fibrodysplasia ossificans progressiva (FOP)
and acquired forms of heterotopic ossification. Several contributory factors have
been suggested, including prostaglandin activity, specifically PGE-2, as well as
hypercalcemia, tissue hypoxia, alterations in sympathetic nerve activity, prolonged
immobilization and imbalances between parathyroid hormone activity and calcitonin [48]. With the discoveries relating cell phenotypes underlying tHO [58-64],
the main cellular process of its development is attributed to the differentiation of
endothelial-derived mesenchymal stem into chondrocytes and osteoblasts. The
micro-environment also plays a role in tHO. When stimulation in the soft tissue
occurs, the inflammation starts to play its important precursor role in forming HO
[65]. The local implantation that releases BMPs, part of the transforming growth
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factor (TGF)-beta superfamily which are central to tissue homeostasis and osteogenesis, induces the formation of the acquired HO [66]. It has been deeply investigated in FOP, that the overactivation of activin receptor-like kinase-2 (ALK2), a
type I BMP receptor, is the cause of the FOP. The inhibition of the BMP receptor
1-mediated BMP/SMAD pathway can therefore effectively inhibit HO [67].
The current treatment and prophylaxis for tHO usually include nonsteroidal antiinflammatory drugs (NSAIDs), radiotherapy, surgical excisions, and physical therapy. In the comparison trial studies, indomethacin showed superior therapeutic
efficacy in preventing HO [68] formation compared to other NSAIDs; i.e. ibuprofen
[69], aspirin [70], or other COX-2 selective NSAIDs [71-73]. However, side effects
typically occur, such as the development of gastrointestinal hemorrhage [68], perforated ulcer [68], and non-selective inhibition of COX-1 leading to the reduction of
thromboxane A2, which is essential to platelet aggregation [69]. Systemic administration of high-dose indomethacin and other NSAIDS for HO prophylaxis also
leads to an imbalance of the formation and resorption of bone. Irradiation therapy
of bone growth and repair was first demonstrated in the 1950s [74], and was established into HO prevention and proven to be effective after hip surgery in 1980s
[75]. Currently, lower dose radiation therapy (RT) is used prophylactically pre- and
post-operatively in patients with bone trauma or operative treatment [76, 77]. The
potential side effects of RT also raise concern, however, such as radiation-induced
carcinoma, bony nonunion, and azoospermia [78]. Bisphosphonate was approved
from Food and Drug Administration (FDA) to treat tHO to reduce the hypercalcemia
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and chemical absorb the calcium, however, limited because its GI toxicity and potential to induce the hypocalcemia and induce the apoptosis of the osteoclast. Surgical excision is sometimes chosen by the patient when partially or completely
restricted range of motion (ROM) is evident. However, postoperative prophylaxis
is still a reliable way to prevent new HO blast formation [79]. Although the goal of
physical therapy in patients with HO is to maintain the ROM and preserve function,
the outcome is debatable, because of the passive stretching may cause microtrauma or local hemorrhage leading to inflammatory conditions [80]. Notably, the
treatment of FOP not only includes what mentioned above, but also high-dose administration of glucocorticoids to reduce lymphocytic infiltration and tissue edema
and treat submandibular swelling [81]. Administration of dexamethasone in particular showed reduced ectopic calcification and limb impairment in ACVR1Q207D
overexpressed mice versus vehicle-treated ACVR1Q207D overexpressed mice
[67]. However, long-term use of corticoids has not been tested clinically due to the
concern of its various side effects [67, 82, 83].
From these disease examples, we learned that the causes, treatments, medical
interventions and financial burdens of different MSDs vary significantly. However,
the MSD also showed similarities, such like underlying inflammatory conditions,
including angiogenesis, inflammatory cell infiltrations, bone, tendon or cartilage involved, which gave the scientists more targets for the drug development strategy
for the better therapeutic efficacy and reduced systemic off-target side effect.
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1.5 Novel Nanomedicine for Treatment and Diagnosis of the Musculoskeletal Disorders
Different from conventional pharmaceutical product, nanomedicine is a promising approach to offer targeted, sustained and controlled release of drugs at the
musculoskeletal pathology. To formulating nanomedicine, we shall understand the
nature of the nanomedicine and the factors which will also influence the nanomedicine itself.
1.5.1 Liposomes
Liposomes have been defined as a vehicle for drug delivery since the 1960s
[84]. Liposomes are composed of spherical bilayer phospholipid membrane surrounded aqueous core separated from the continuous aqueous solvent. According
to the number of lipid layers and the size of the liposomes, they can be categorized
into multilamellar vesicle (MLV) [85], small unilamellar vesicle (SUV) [86] and large
unilamellar vesicle (LUV) [87]. As drug delivery systems, liposomes have been
applied to encapsulate both hydrophobic and hydrophilic drug. Besides its wide
drug category loading capacity, liposomes delivery system can also protect the
cargoes from enzymatic degradation or oxidation and enhance the intracellular uptake. To ensure their stealth against the mononuclear phagocyte system (MPS)
liposome formulations can be decorated with inert water-soluble polymers (e.g.,
PEG, HPMA copolymer, etc.). For certain purpose, targeting moieties or imaging
probes can also be used to modify the surface of the liposomes. The first FDA
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approved nano-drug, liposomal-doxorubicin (also called Doxil or Lipodox or Myocet), was approved to use on the treatment of several cancer disease including
the treatment of soft tissue sarcomas [88-90].
1.5.2 Micelles
Micelles are amphiphilic molecules consisted self-assembled colloidal systems,
which can spontaneously aggregate into particles at a concentration higher than
the critical micelle concentration (CMC). The size and the shape of the micelle
can varie from 10 nm to over 100 nm, spherical [91], ellipsoid cylindered, wormlike or monolayer micelle [92]. A typical micelle has hydrophilic tails forming a shell
structure, and the inner hydrophobic structure can encapsulate or conjugate with
poorly water-soluble drugs. This structure can be achieved using three types of
the macromolecular drugs: 1. The molecule is composed of the one polar end (hydrophilic group) and one non-polar end (hydrophobic group) [93]. 2. Two polar
ends with the non-polar center [91]. 3. Two non-polar ends with the polar center
[94]. There are no FDA approved micellar drugs to treat MSDs now, however there
are many researchers investigating on this type of nanomedicine [95]. Xu, et al.
developed a conjugation system of sialic acid-dextran-octadecanoic acid (SA-DexOA), which can self-assemble into micelle and load with the anti-rheumatic drug
(methotrexate, MTX). The significant higher bone mineral density in the adjuvant
induced arthritis rats treated with MTX-loaded SA-Dex-OA micelles as compared
to in those treated with free MTX and Dex-OA/MTX micelles may be contributed
to not only the MTX prevention on bone erosion but also the effect of promoting
MC3T3-E1 cell differentiation and mineralization by endogenous sialic acid [96].
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Investigators, Low, et al. also cooperated the aspartic acid oligopeptides, which
adsorb to hydroxyapatite, the mineral portion of bone, in their micelle formulation.
The adsorption of this aspartic acid oligopeptides and hydroxyapatite is the strongest where bone turnover is highest or where hydroxyapatite is freshly exposed,
such like in the condition of bone fracture. The biodistribution study of this aspartic
acid oligopeptides containing micelle conjugated with the

125I

labeled anabolic

agent, GSK3β Inhibitor showed a preferential accumulation of the micelle after a
i.v. systemic injection to the fracture site in the murine model [97]. The improved
fracture repair by this micellar drug and its branch derivative were shown in the
same animal model [98].
1.5.3 Nanoparticles
Nanoparticles can be categorized as drug nanoparticles, solid nanoparticles,
polymer-based nanoparticles, lipid-based nanoparticles and nanocapsules. Drug
nanoparticles or so-called nanosuspension are dispersed water-insoluble drug
particles in the nano-size range in an aqueous environment. Drug nanoparticles
can be achieved by breaking down the bigger particles by high-pressure homogenization method or by special crystallization techniques. Polymer-based nanoparticles are commonly composed of poly(lactic acid) (PLA), poly(glycolicacid) (PGA),
poly (lactic acid-co-glycolic acid) (PLGA), poly(ε-caprolactone) (PCL), and
poly(methylmethacrylate) (PMMA). Chemical synthesis, salting-out, emulsification-diffusion, nanoprecipitation and freeze-drying methods are used to obtain polymer-based nanoparticles. Lipid-based nanoparticles mostly composed of fats or
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waxes and can be obtained by homogenization. For certain applications, nanoparticles may be tailored into different shape, such as sphere nanoparticles [99],
cube nanoparticles [100], rod-like nanoparticles [101], hollow spherical nanoparticles [102] and random shape nanoparticles. The use of the FDA approved nanoparticle drug or medical material used for the MSD conditions are mostly for the
bone mimics, such like EquivaBone (Zimmer Biomet) [103], NanOss (RTI Surgical)
[104], Ostim (Heraeus Kulzer) [105, 106], OsSatura (IsoTis Orthobiologics) [107],
Vitoss (Stryker) [108]. These nanoparticles can provide a nanostructure with more
surface area which allowed increased potential for cell attachment, and the similarity to nature bone, which increases the potential to remodel into new bone. Under the same category of nanoparticles, there are a sub-category of the
nanoparticles are approved by FDA to be used as the diagnostic tool, e.g. superparamagnetic nanoparticle, Magnevist, was approved by FDA as a contrast agent
for magnetic resonance imaging to facilitate the visualization of lesions with abnormal vascularity in the body [109].
1.5.4 Dendrimers.
Dendrimers are highly uniformed, branched or star-shaped macromolecules.
Dendrimers can be synthesized by divergent [110] or convergent approaches [111].
They are often of uniform molecular weight and very low polydispersities. Dendrimers also have modifiable surface functional group as well as internal cavities
[112]. For example, Newkome et al. [113] have synthesized a dendrimer containing hydrophobic interior and hydrophilic surface functionality. During or after synthesis of dendrimers, the drug molecules can be physically entrapped or
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chemically conjugated to the dendrimer [114]. There are no FDA approved dendrimer drug to treat MSDs, however, researchers has put efforts on developing the
bone-targeting dendrimers such as Yamamoto group has developed aspartic acid
conjugated PAMAM dendrimer or alendronate conjugated PAMAM dendrimer,
those dendrimers showed strong targeting effect to the bone tissue [115, 116].
When the alendronate conjugated dendrimer loaded with MTX and administrated
to a bone metastasis murine model, the pharmacokinetics and therapeutic effect
showed a preferential accumulation of the dendrimer to the bone tissue and a significant lower cancer cells proliferated in the metastasis site.
1.5.5 Macromolecular conjugates.
Macromolecular prodrug or polymeric conjugates which have a hydrodynamic
diameter of less than 10 nm [117] may result in much less RES uptake and provide
a better-controlled drug releasing profile by optimizing the covalent bond or linker
between the drug and the carrier backbone. Previously, in our lab, we have developed and tested a macromolecular theranostic system that has the capacity to
detect early signs of wear particle-induced peri-implant granulomatous inflammation, and in addition to deliver potent anti-inflammatory and/or anti-bone resorptive
agents specifically to the peri-implant tissues with minimal “off-target” side effects.
Conceptually, this system is based upon our discovery that macromolecular
theranostic agents can specifically target to sites of inflammation and undergo uptake and activation by inflammatory cells [118, 119]. Besides HPMA conjugated
macromolecular polymer drug, the PEGylated drug conjugates have also shown
its promise in the drug delivery system development. These conjugates have a
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large population in the list of the approved of FDA approved nanomedicine, among
which pegloticase (Krystexxa; Savient Pharmaceuticals), FDA approved
PEGylated porcine-like uricase, showed a significant decrease of plasma uric acid
level in about 40% of patients suffered with chronic gout (associated with a tendency for tophi dissolution) [120]. The nanoformulation improved stability of protein through PEGylation, however, the targeting, retention and reduction
immunogenic uricases of the drug still need to be developed since there were
about 60% patients showed no change of their disease progression.
The great challenge for the development of the nanomedicine to treat or and
diagnose the MSDs also remains a great opportunity for the researchers to develop smarter and safer drug delivery systems and diagnostics. These smarter
and safer tools with the tropism to the MSD site may use different targeting strategies.
1.6 Targeting strategies
After choosing the delivery tool for drug, scientists made tremendous efforts to
modify the delivery system to obtain a better targeting property to further enhance
the therapeutic efficacy and reduce the off-target systemic toxicity. Fortunately,
MSDs have many unique features that can help nanomedicines differentiate the
disease site with normal site and benefit them with a sustained retention.
1.6.1 Passive targeting
In 1979, the antitumor protein drug neocarzinostatin (NCS) was conjugated
with a synthetic copolymer of styrene maleic acid copolymer (SMA) which was
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called SMANCS (molecular weight 16,000 g/mol) by Maeda [121]. This antitumor
protein drug conjugate exhibited many unique properties, including prolonged halflife in circulation (20-fold), improved tumor-targeting capacity (2000 fold intra-tumor concentration than plasma), no immunogenicity and higher lipophilicity [122124]. These properties led to the conceptualization of the Enhanced Permeability
and Retention effect (EPR effect) [125].

With the advantage of EPR effect,

SMANCS became the first macromolecular anticancer drug approved in 1993 in
Japan [122]. The EPR effect has been observed in the applications of many nanomedicine formulations, such as polymer conjugates, polymeric micelles and liposomes [126, 127]. Most HPMA copolymers utilize the EPR effect to achieve
better tumor targeting and delivery of drugs. EPR effect is a tumor vasculaturedependent phenomenon. Most tumors are well vascularized with high density and
the rapid growth of blood vessels leads to irregular vascular alignment and defects
of the junction between endothelial cells. The increased local fenestration of macromolecules paired with the ill-developed lymphatic drainage at the tumor lesion
lead to the local accumulation of macromolecules over time [122, 128-132]. Wang
et al. first described macromolecules’ Extravasation through Leaky Vasculature
and their subsequent Inflammatory cell-mediated Sequestration (ELVIS) [133]. It
explains the passive targeting of the HPMA copolymer–dexamethasone conjugate
(P-Dex) to inflammations [134, 135]. Unlike the traditional understanding of EPR
effect that macromolecules only can passively target to solid tumors (not inflammation) due to the leaky vasculature and impaired lymphatic drainage, they found
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although the extravasated macromolecules are cleared from the inflammatory tissue quickly, rapid internalization by inflammatory infiltrates and locally activated
cells provide the mechanism for the sustained retention of the macromolecular
drug conjugate at the site of inflammation.
1.6.2 Active targeting
The use of passive targeting mechanism is that researchers are taking the advantages of the nature of disease site, such like the EPR effect at tumor site and
ELIVIS effect at inflammation site. Different from this smart design, researchers
also utilized many active targeting strategy to target and keep the drugs at the
musculoskeletal sites. Because of those unique features of the musculoskeletal
system, we can design the drugs with the targeting moieties with higher affinities
to those tissues.
1.6.2.1 Bone targeting
Bone system is the hardest system in the body because of the needle-like crystals composed by organic matrix and inorganic mineral phase of hydroxyapaptite
(HA) [136]. Researchers choose to target the mineral composition (apatite) of the
bone to obtain osteotropicity due to its biggest composition in bone and difficulties
to target the organic matrix (such as the collagens which is ubiquitous in the body).
There are many bone-targeting moieties can be utilized in the bone targeting drugs,
including: 1. Tetracyclines have well-defined metal complexing abilities [137] and
the nature of their chelation with surface calcium ions in bones [138]; 2. Pyrophosphate, bisphosphate, or alendronate can chelate the calcium ions because of their
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phosphate structure [139], 3. Polymeric amino acid specific with certain sequence
and abundance of the such amino acids like Asp, Glu, Gla or phosphorylated
Ser/Thr can show the controlled nucleation capacity [2]. Some of those bone targeting moieties have its own cellular medical or toxicity effect, ones need to pay
much attention when conjugating them to the nanomedicine or nanodiagnostics.
1.6.2.2 Tendon targeting
Unlike bone targeting, there is no many strategies for tendon targeting. However, researchers have found that the muscle cells migration has its own direction
which will end at the tendon tissue. Tendon cells here are crucial in providing
guidance for muscle migration by the formation of the complex between its type1
transmembrane protein, which containing a leucine-richrepeat (LRR) domain in its
extracellular region, and the Robo proteins in the muscle cells. This natural crosscommunication with the existing targeting mechanism behind may inspire the drug
delivery scientists in designing the drug to treat tendon disease [140].
1.6.2.3 Cartilage targeting
Drugs that can be injected intra-articular still face to another challenge that it is
difficult to have enough drug penetrating into the cartilage tissue and reach the cell
and matrix tissue. This is not only because of the highly charged oligosaccharides
introducing an effective polar barrier for penetration of lipophilic drug molecules,
but also an intrinsic challenge results from the fact that low-molecular-weight solutes in the joint will be eliminated due to the convective transport and lymphatic
uptake. Researchers have investigated using the addition of cationic domains or
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proteins that favorable bind-to heparan sulfate or the glycosaminoglycan binding
domain to obtain the longer retention at the intra-articular site and deeper penetration to the chondrocytes using the drug delivery carrier.
While the large amount of unmet medical needs of the drugs for the treatment
and diagnosis of the musculoskeletal diseases remained, the nature of those types
of diseases also provide the unique opportunities for the development and optimization of the targeted drug delivery system. In the following chapters, we will introduce our work on development of macromolecular prodrug conjugates for the
diagnosis and treatment of musculoskeletal diseases.
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CHAPTER 2
DESIGN, SYNTHESIS AND CHARACTERIZATION OF MACROMOLECULAR
PRODRUG WITH DIFFERENT MOLECULAR WEIGHT, DRUG COTENT, AND
DRUG-CONTAINING MONOMER
2.1 Introduction
As discussed in Chapter 1, to meet the clinical need for the treatment and early
detection of the implant lossening, we have explored the potential utility of N-(2hydroxypropyl) methacrylamide (HPMA) copolymer conjugates as a theranostic
platform for early diagnosis and prophylactic treatment of peri-prosthetic osteolysis.
[118, 141]. Because of the nature of this synthetic, water-soluble polymer-based
theranostic platform, structural parameters (such as average molecular weight
(MW), drug loading, and the presence of active targeting ligands) are all known to
have significant impact on the platform’s in vivo pharmacokinetic and biodistribution (PK/BD) profile. In addition, the pathophysiology features (e.g., inflammation)
may have a profound impact on the platform’s in vivo fate. HPMA copolymer conjugates’ PK/BD profiles have been characterized in multiple animal models of human diseases. [142-144] In this chapter, we will focus on synthesizing a series of
HPMA copolymers with different molecular weight (MW) and/or Dex contents
which were labeled using Alexa Flour® 488, IRDye 800 CW, and radio isotope 125I
respectively for the following in vitro and in vivo evaluation (Figure 2. 1); and HPMA
copolymers with different Dex containing monomer (Figure 2. 2) to provide different
releasing rates for the in vitro releasing characterization and in vivo therapeutic
investigation.
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Figure 2. 1 General structure of the HPMA copolymer conjugates.
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Figure 2. 2 Chemical structure of different Dex containing monomer.
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2.2 Materials and Methods
2.2.1 Materials
N-(2-Hydroxypropyl) methacrylamide (HPMA), N-methacryloyl glycylglycyl hydrazinyl dexamethasone (MA-Dex), N-methacryloyl tyrosine amide (MA-Tyr-NH2),
and S,S′-bis(α,α′-dimethyl-α″-acetic acid)-trithiocarbonate (CTA, purity >97%)
were prepared as reported previously [145]. Sephadex LH-20 resin and PD-10
columns were obtained from GE HealthCare (Piscataway, NJ). The Na 125I was
purchased from PerkinElmer (Waltham, MA). IRDye 800CW NHS ester was purchased from LI-COR, Inc. (Lincoln, NE). Alexa Fluor® 488 NHS ester was purchased from Life Technologies (Eugene, OR). All other reagents and solvents
were purchased from either Sigma-Aldrich (St. Louis, MO) or Acros Organics (Morris Plains, NJ). All compounds were reagent grade or higher and used without
further purification.
2.2.2 Instruments
1H

and 13C NMR spectra were recorded on a 500 MHz NMR spectrometer (Var-

ian, Palo Alto, CA). A lambda 10 UV/vis Spectrometer (PerkinElmer, Waltham,
MA) was used for UV/vis spectrophotometric analyses. A ÄKTA Fast Protein Liquid Chromatography system (FPLC, GE Healthcare Bio-Sciences, Pittsburgh, PA)
equipped with Superdex 200 column, UV, and RI (KNAUER, Berlin, Germany) detectors was used for analyses of P-Dex molecular weight. HPLC analyses were
performed on an Agilent 1100 HPLC system (Agilent Technologies, Inc., Santa
Clara, CA) with a reverse phase C18 column (Agilent, 4.6 × 250 mm, 5 μm).
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Zetasizer Nano ZS90 (Malvern, Worcestershire, UK) was used in P-Dex aggregation analyses.
2.2.3 Synthesis of the macromolecular prodrugs with different molecular weight
and drug content
The HPMA copolymer-dexamethasone conjugates were synthesized by a reversible addition−fragmentation chain transfer (RAFT) copolymerization as described previously [146].

N-(2-Hydroxypropyl) methacrylamide (HPMA), N-

methacryloyl glycylglycyl hydrazinyl dexamethasone (MA-Dex), and N-methacryloyl tyrosine amide (MA-Tyr-NH2) were dissolved in anhydrous methanol and then
copolymerized under argon at 45 °C for 48 h with 2,2″-azobis(isobutyronitrile)
(AIBN) as an initiator and S,S′-bis(α,α′-dimethyl-α″-acetic acid) trithiocarbonate
(CTA) as the RAFT agent. The ratio of AIBN and CTA was adjusted to obtain
HPMA copolymer-dexamethasone conjugates (P-Dex) with different molecular
weight, and the dexamethasone (Dex) content was regulated by adjusting the MADex feed-in ratio (Table 2. 1). The final tyrosine amide-containing HPMA copolymer-Dex conjugates (P-Dex-Tyr-NH2) were obtained by lyophilization after the removal of the unreacted low molecular weight compounds using LH-20 column.
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P-Dex-15 kDa-12%
Molar ratio (%)

Mw (g/mol)

mmol

mg

HPMA

89.84

143.20

2.7933

400.00

MA-Dex

6.41

588.70

0.1992

117.26

AIBN

1.78

168.75

0.0554

9.35

CTA

0.99

264.70

0.0308

8.14

APMA

0.99

178.57

0.0306

5.47

METHANOL

3.74 mL
P-Dex-25 kDa-12%
Molar ratio (%)

Mw (g/mol)

mmol

mg

HPMA

91.05

143.20

2.7933

400.00

MA-Dex

6.49

588.70

0.1992

117.26

AIBN

0.94

168.75

0.0288

4.86

CTA

0.52

264.70

0.0160

4.24

APMA

1.00

178.57

0.0306

5.47

METHANOL

3.74 mL
P-Dex-35 kDa-12%
Molar ratio (%)

Mw (g/mol)

mmol

mg

HPMA

91.48

143.20

2.7933

400.00

MA-Dex

6.48

588.70

0.1979

116.49

AIBN

0.67

168.75

0.0206

3.47

CTA

0.37

264.70

0.0114

3.03
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APMA

1.00

178.57

METHANOL

0.0304

5.44

3.74 mL
P-Dex-45 kDa-12%
Molar ratio (%)

Mw (g/mol)

mmol

mg

HPMA

91.64

143.20

2.7933

400.00

MA-Dex

6.49

588.70

0.1979

116.49

AIBN

0.56

168.75

0.0171

2.89

CTA

0.31

264.70

0.0095

2.52

APMA

1.00

178.57

0.0304

5.44

METHANOL

3.74 mL
P-Dex-20 kDa-12%
Molar ratio (%)

Mw (g/mol)

mmol

mg

HPMA

89.40

143.20

2.7933

400.00

MA-Dex

6.50

588.70

0.2031

119.57

AIBN

2.00

168.75

0.0623

10.24

CTA

1.11

264.70

0.0346

9.78

MA-Tyr-NH2

1.00

248.30

0.0312

7.76

METHANOL

3.74 mL
P-Dex-30 kDa-12%
Molar ratio (%)

Mw (g/mol)

mmol

mg

HPMA

90.93

143.20

2.7933

400.00

MA-Dex

6.50

588.70

0.1997

117.55

25

AIBN

1.01

168.75

0.0311

5.10

CTA

0.56

264.70

0.0173

4.87

APMA

1.00

248.30

0.0307

7.63

METHANOL

3.74 mL
P-Dex-40 kDa-12%
Molar ratio (%)

Mw (g/mol)

mmol

mg

HPMA

91.45

143.20

2.7933

400.00

MA-Dex

6.50

588.70

0.1985

116.88

AIBN

0.68

168.75

0.0207

3.40

CTA

0.38

264.70

0.0115

3.24

MA-Tyr-NH2

1.00

248.30

0.0305

7.58

METHANOL

3.74 mL
P-Dex-30 kDa-6%
Molar ratio (%)

Mw (g/mol)

mmol

mg

HPMA

94.31

143.20

3.4916

500.00

MA-Dex

3.25

588.70

0.1203

70.83

AIBN

0.93

168.75

0.0343

5.62

CTA

0.51

264.70

0.0190

5.37

APMA

1.00

248.30

0.0370

9.19

mmol

mg

METHANOL

4.15 mL
P-Dex-30 kDa-0%
Molar ratio (%)

Mw (g/mol)

26

HPMA

97.69

143.20

3.4916

500.00

MA-Dex

0.00

588.70

0.0000

0.00

AIBN

0.84

168.75

0.0300

4.93

CTA

0.47

264.70

0.0167

4.66

APMA

1.00

248.30

0.0357

8.87

METHANOL

4.15 mL

Table 2. 1 Feed-in ratio of the AIBN, CTA, HPMA and MA-Dex, was adjusted to
obtain HPMA copolymer-dexamethasone conjugates (P-Dex) with different molecular weight, and the dexamethasone (Dex) content.
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2.2.4 Synthesis of

125I

labeled P-Dex (P-Dex-125I)

To label the P-Dex-Tyr-NH2 with

125I,

the tyrosine containing copolymers (∼1

mg) were dissolved in saline (50 μL, 0.9%) in a glass vial (1 mL). Chloramine-T
(100 μL, 4.8 mg/mL, saline) and NaI125 solution (pH = 12, 20 μL, 1 mCi) were
sequentially added to the solution. This reaction was stirred at room temperature
(0.5 h) and quenched by Na2S2O3 (6 mg/mL, in 100 μL saline). After purification
by PD-10 column, twice, the resulting solution (1.5 mL) was obtained with strong
radioactivity (∼0.08−0.12 mCi). The entire labeling process was done according
to a protocol approved by the University of Nebraska Medical Center Radiation
Safety Office in a fume hood with face velocity of 100 FPM and with lead shield
protection. Post labeling cleaning and contamination survey were performed to
ensure the absence of any radiation contamination in the working area.
2.2.5 Synthesis of IRDye 800CW-labeled P-Dex (P-Dex-IRDye)
P-Dex-APMA (the copolymers of HPMA and N-(3-aminopropyl) methacrylamide,10 50 mg, containing ∼0.0037 mmol of amine) and IRDye 800CW NHS ester
(1.25 mg, 0.001075 mmol LI-COR Biosciences, Lincoln, NE) were dissolved in dimethylformamide (DMF, 900 μL) with 15 μL of N,N-diisopropylethylamine (DIPEA)
added. The solution was stirred overnight in darkness at room temperature. The
product was then purified on an LH-20 column and lyophilized. The IRDye 800CW
content was determined using Lambda 10 UV/vis Spectrometer.
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2.2.6 Synthesis of Alexa Fluor® 488 labeled P-Dex (P-Dex-Alexa)
P-Dex-APMA (50.0 mg, containing ∼0.0037 mmol of amine) and Alexa Fluor
488 NHS ester (0.75 mg, 0.001 mmol, Life Technologies, Eugene, OR) dissolved
in DMF (900 μL) with DIPEA (15 μL) added. The mixture was stirred overnight in
darkness at room temperature. The product was then purified on an LH-20 column
and lyophilized. The Alexa Fluor 488 content was determined using a Lambda 10
UV/vis Spectrometer.
2.2.7 Synthesis of HPMA copolymer conjugates with different Dex-containing
monomer (P-Dex-A, P-Dex-B, P-Dex-C, P-Dex-D)
2.2.7.1 Synthesis of Monomer A
As shown in Figure 2.3,dexamethasone and imidazole were dissolved in anhydrous DMF and the solution was cooled to 0 °C by ice bath. TBSCl was added.
The solution was stirred at 0 °C for 1h and then allowed to room temperature for
3h. Ethyl acetate (200 ml) was added and the solution was then washed with
saturated brine. The organic phase was then dried over Na2SO4 and then the
solvent was removed to get crude product 1.
The crude product was then dissolved in a solution of hydrazine monohydrate
in methanol, and then acetic acid was added. The solution was stirred at room
temperature for 4h. Ethyl acetate was added and the solution was then washed
with saturated brine. The organic phase was then dried over Na2SO4 and then the
solvent was removed to get the residue. Flash column chromatography to give
product 2. Some compound 1 was recovered.
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N-(3-aminopropyl)methacrylamide hydrochloride and Et3N were dissolved in
anhydrous DMF at 0 °C. Mono-methyl terephthalate and DCC were then added.
The solution was stirred at room temperature for 6h. Ethyl acetate was added and
the solution was then washed with saturated brine. The organic phase was then
dried over Na2SO4 and then the solvent was removed. The residue was purified
by column chromatography to give product 3.
Compound 3 was dissolved in a mixture of water and methanol, KOH was then
added. The solution was stirred at room temperature overnight. HCl solution was
added to neutralize the KOH. Ethyl acetate was used to extract the product from
the aqueous phase. Then the solvent was removed, the residue was purified by
flash chromatography to give the product 4.
Compound 2, DCC, HOBt and DIPEA were dissolved in anhydrous DMF, then
compound 4 was added. The solution was stirred at room temperature 3h. Ethyl
acetate was added and the solution was then washed with saturated brine. The
organic phase was then dried over Na2SO4 and then the solvent was removed.
The residue was purified by column chromatography to give product 5.
Compound 5 was dissolved in THF and TBAF (1M, THF) was added. The
solution was stirred at room temperature for 1h. Ethyl acetate was added and the
solution was then washed with saturated brine. The organic phase was then dried
over Na2SO4 and then the solvent was removed. The residue was purified by
column chromatography to give product 6 (Monomer A).
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Figure 2.3 Synthesis route of Monomer A.
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2.2.7.2 Synthesis of Monomer B
As shown in Figure 2.4 compound 2 and methyl bromoacetate were dissolved
in anhydrous DMF, potassium carbonate was then added to the solution. The
solution was heated to 80°C for 2h. Ethyl acetate was added and the solution was
then washed with saturated brine. The organic phase was then dried over Na2SO4
and then the solvent was removed. The residue was purified by column chromatography to give product 7.
Compound 7 and 1,3-diaminopropane were dissolved in MeOH. The solution
was stirred at room temperature overnight. Ethyl acetate was added and the solution was then washed with saturated brine. The organic phase was then dried
over Na2SO4 and then the solvent was removed to give the crude product 8.
The crude compound 8 and triethylamine were dissolved in dichloromethane.
The solution was then cooled to 0°C with ice-water bath. The methacryl chloride
in dichloromethane was added dropwise. After addition, the solution was then
stirred 1 hour at 0°C for 1h. Ethyl acetate was added and the solution was then
washed with saturated brine. The organic phase was then dried over Na2SO4 and
then the solvent was removed. The residue was purified by column chromatography to give product 9.
Compound 9 was dissolved in THF and TBAF (1M, THF) was added. The
solution was stirred at room temperature for 1h. Ethyl acetate was added and the
solution was then washed with saturated brine. The organic phase was then dried
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over Na2SO4 and then the solvent was removed. The residue was purified by
column chromatography to give product 10 (Monomer B).
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Figure 2. 4 Synthesis route of Monomer B
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2.2.7.3 Synthesis of Monomer C
As shown in Figure 2.5, the isomer of compound 2 is a byproduct of the reaction
of preparing compound 2. It was dissolved in anhydrous DMF with DCC. The
solution was cooled to 0°C with ice-water bath and then added MA-Gly-Gly-OH
and DMAP. The solution was stirred at 0°C for 3h. Ethyl acetate was added and
the solution was then washed with saturated brine. The organic phase was then
dried over Na2SO4 and then the solvent was removed. The residue was purified
by column chromatography to give product 11.
Compound 11 was dissolved in THF and TBAF (1M, THF) was added. The
solution was stirred at room temperature for 1h. Ethyl acetate was added and the
solution was then washed with saturated brine. The organic phase was then dried
over Na2SO4 and then the solvent was removed. The residue was purified by
column chromatography to give product 12 (Monomer C).
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Figure 2. 5 Synthesis route of Monomer C
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2.2.7.4 Synthesis of Monomer D
To get Monomer D, dexamethasone, DMAP and triethylamine were dissolved
in anhydrous dichloromethane. The solution was cooled to 0°C with ice-water bath
and then methacryl chloride in dichloromethane was added dropwise. The solution
was then stirred 1 hour at 0°C for 1h. Ethyl acetate was added and the solution
was then washed with saturated brine. The organic phase was dried over Na2SO4
and the solvent was removed. The residue was purified by column chromatography to give product 13 (Monomer D, shown in Figure 2.6).

37

Figure 2. 6 Synthesis route of Monomer D
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2.2.8 Characterization of the HPMA copolymer conjugates
Size exclusion chromatography (SEC) with an ÄKTA fast protein liquid chromatography (FPLC) system was used to determine the number-average molecular
weight (Mn), weight-average molecular weight (Mw), and the polydispersity index
(PDI) of the copolymers using a calibration of HPMA homopolymers with narrow
PDI. To quantify Dex content in P-Dex, the copolymers were hydrolyzed in 0.1 N
HCl (1 mg/ mL) overnight. The resulting solution was neutralized and analyzed on
an Agilent 1100 high performance liquid chromatography (HPLC) system with a
reverse phase C18 column (Agilent, 4.6 × 250 mm, 5 μm). Mobile phase, acetonitrile/water 2:3; detection, UV 240 nm; flow rate, 1 mL/ min; injection volume, 10 μL.
The analyses were performed in triplicate. The mean value and standard deviation
were obtained using Excel. The characterizations of all HPMA copolymer conjugates used in this study are summarized in Tables 2.2 and 2.3. The potential
aggregation of the P-Dex (6 wt%) was characterized by DLS with a series of concentrations. Three measurements at each concentration were performed, and the
results were averaged and summarized in Table 2.5.
The Dex content analysis of the HPMA copolymer with different Dex-containing
monomers is as similar as described above. The weight average molecular weight
(Mw), number of molecular weight (Mn) polydispersity (PDI) and Rayleigh Ratio
(RΘ, dn/dc) of the P-Dex-A, P-Dex-B, P-Dex-C, and P-Dex-D were analyzed using
a combination of AKTÄ pure FPLC system, Wyatt multiangle light scattering system and Optilab T-rEX refractive index concentration detector. In vitro releasing
profile of the P-Dex (for a clear comparison, we named P-Dex as P-Dex-E in all

39

the following study related with the different releasing rate polymers evaluation),
P-Dex-A, P-Dex-B, P-Dex-C, and P-Dex-D was conducted in different pH buffered
solution (pH 5.0 acetate buffer, pH 6.0 acetate buffer, pH 7.0, pH7.4 and pH 8.7
phosphate buffer, pH 11 sodium carbonate buffer, human serum and rat serum).
The copolymers were weighted and dissolved in to different buffer to the concentration of 4 mg/mL (polymer/solution) with Pluronic F127 (1 wt% of total Dex) added
to create the “sink” condition. The copolymer-containing solutions were then fixed
into a shaking incubator (60 r/min) at 37 °C. At pre-designed time points, the releasing solutions were withdrawn, neutralized and then extracted with 9 times in
volume of METB. The 1/3 volume of METB was then withdrawn and evaporated
using vacuum evaporator. (eg. 50 uL samples released in pH 4.5 solution was
withdrawn and neutralized using 6.5 uL pH 10 solution. Then 508.5 uL METB was
added for extraction and 169.5 uL METB supernatant was withdrawn followed with
the solvent evaporated using vacuum evaporator.

The residues were resus-

pended into 100 uL H2O/MeOH solution (H2O/MeOH=1:9) for HPLC injection).
The HPLC analyses was based on the standard curve using dexamethasone base
under the same flowing condition to determine the free Dex concentration. The
METB extraction recovery rate was analyzed using the same method in the in vitro
releasing part within the Dex concentration from 5-500 µg/mL.
2.3 Results
2.3.1 Characterization of HPMA copolymer conjugates
The synthesis of all the HPMA copolymer-dexamethasone conjugates and their
labeling with 125I and fluorescent labels were straightforward [146]. By employing
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RAFT copolymerization, we were able to control the MW of the HPMA copolymer
conjugates and manage their PDI in a narrow range as shown in Tables 2.2 and
2.3. The dynamic light scattering analysis results of P-Dex copolymers with different MW and Dex content were presented in Table 2.4 and results for P-Dex-35
kDa-6% at different concentration can be seen in Table 2.5. The DLS data clearly
suggest that P-Dex-35 kDa-6% forms aggregates under the conditions tested. This
finding may partially explain the unexpected fast clearance of P-Dex-35 kDa-6%
found in the PK/BD study.
The HPMA copolymer conjugates with different monomers were characterized
as described above. The results shown in Table 2.6 represented the MW and PDI
of the polymers were as designed. The relatively low drug content in the P-Dex-B
may be the result of the potential releasing of the Dex from the fast releasing
monomer B during the polymerization.
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Mw
Polymer
(× 103

Dex content

Radioactivity

(μmol/g)

(μCi/g)

PDI

conjugates
g/mol)
P-Dex-20 kDa-12%

20.5

1.11

283.09 ± 35.16

138.8

P-Dex-30 kDa-12%

30.7

1.18

346.28 ± 10.70

394.8

P-Dex-40 kDa-12%

39.1

1.21

341.94 ± 25.98

354.8

P-Dex-30 kDa-6%

35.3

1.17

170.46 ± 22.42

200.4

P-Dex-30 kDa-0%

30.8

0

180.8

1.06

Table 2.2 The characterization of HPMA copolymer conjugates labeled with
Mw: weight average molecular weight; PDI: polydispersity index.

125I.
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Mw

[IRDye

Polymer
(×103

Dex Content

[Alexa 488]

(μmol/g)

(μmol/g)

800CW]

PDI

conjugates

(μmol/g)

g/mol)
P-Dex-15 kDa-12%

15.9

1.35 306.55 ± 27.24 10.89 ± 0.15 6.20 ± 0.14

P-Dex-25 kDa-12%

27.5

1.4

P-Dex-35 kDa-12%

35.3

1.49 356.34 ± 39.55 10.25 ± 0.20 7.89 ± 0.04

P-Dex-45 kDa-12%

45.3

1.34 315.32 ± 18.40 12.63 ± 1.28 7.55 ± 0.14

P-Dex-35 kDa-6%

35.7

1.29 168.86 ± 20.33 11.83 ± 0.38 7.54 ± 0.10

P-Dex-35 kDa-0%

36.0

1.45

300.13 ± 11.23 13.82 ± 0.27 6.08 ± 0.31

0

13.50 ± 0.30 7.83 ± 0.11

Table 2.3 The characterization of HPMA copolymer conjugates labeled with fluorescent probes. Mw: weight average molecular weight; PDI: polydispersity index;
Dexamethasone content; [Alexa-488]: Alexa Fluor® 488 content; [IRDye-800CW]:
IRDye 800CW content.
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Sample

P-Dex-15

P-Dex-35

P-Dex-45

P-Dex-35

P-Dex-35

Name

kDa-12%

kDa-12%

kDa-12%

kDa-6%

kDa-0%

6.643

7.673

8.552

163.9

6.828

0.237

0.318

0.209

0.481

0.174

Z-Ave
(d.nm)
PDI

Table 2.4 Result of dynamic light scattering characterization of polymers at a
concentration of 5 mg/mL. Z-Ave: Z-Average size (diameter.nm); PDI: Polydispersity index.
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Concentration
5

37.5

150

Z-Ave (d.nm)

163.9

282.9

313.6

PDI

0.481

0.769

1

(mg/mL)

Table 2.5 Result of dynamic light scattering characterization of P-Dex-35 kDa-6%
at different concentration. Z-Ave: Z-Average size (diameter. nm); PDI: Polydispersity index.
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Polymer
conjugates

Mw
(×103

PDI

Dex Content (μmol/g)

g/mol)

P-Dex-A

35.8

1.32

329.76 ± 8.80

P-Dex-B

36.7

1.36

113.61 ± 13.19

P-Dex-C

35.4

1.13

418.27 ± 12.63

P-Dex-D

31.9

1.48

303.66 ± 9.22

P-Dex-E

39.1

1.23

258.11 ± 6.40

Table 2.6 The characterization of HPMA copolymer conjugates conjugated with
different Dex-containing monomers. Mw: weight average molecular weight; PDI:
polydispersity index.
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2.3.2 In Vitro release profile of the P-Dex-A, P-Dex-B, P-Dex-C, P-Dex-D, P-DexE in different releasing buffer
The in vitro Dex release was studied by incubating P-Dex-A, P-Dex-B, P-DexC, P-Dex-D, P-Dex-E in pH 5.0, pH 6.0, pH 7.0, pH 7.4, pH 8.7, pH 11.0, human
serum and rat serum at 37°C (Figure 2.7). The polymers all showed different releasing rates in different buffers. When comparing the rates under the same buffer,
different polymers released with differently rates. The releasing rates sequence
also changed when the buffer changed (Figure 2.8). For example, under acidic
condition, pH 4.5 and pH 5.5, the releasing rate trend was RP-Dex-B > RP-Dex-C > RPDex-D

> RP-Dex-E > RP-Dex-A. Under biological PBS buffer (pH 7.4) the releasing rate

trend was RP-Dex-D > RP-Dex-B > RP-Dex-C > RP-Dex > RP-Dex-A. Under basic condition
(pH 10), considering the self-degradation of Dex, the releasing rate trend in the
first 3 days was used to compare: RP-Dex-D > RP-Dex-C > RP-Dex-B > RP-Dex-A > RP-Dex.
The recovery rate was 97.18 ± 2.6%
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Figure 2.7 In Vitro Dex release from P-Dex P-Dex-A, P-Dex-B, P-Dex-C, P-Dex-D,
P-Dex-E. The polymers showed different releasing rates under different pH. Each
sample was measured three times. The mean values and standard deviation were
calculated using GraphPad Prism 7.
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Figure 2.8 In Vitro Dex release from P-Dex P-Dex-A, P-Dex-B, P-Dex-C, P-Dex-D,
P-Dex-E at different releasing solution (pH=5.0, 6.5, 7.0, 7.4, 8.7 and 11, human
serum and rat serum). Each sample was measured three times. The mean values
and standard deviation were calculated using GraphPad Prism 7.
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2.4 Discussion
The passive targeting of nanomedicines, including water-soluble macromolecules after systemic administration, has been validated in multiple animal models
of inflammatory diseases, which encompass chronic systemic autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus), acute local injuries (e.g., fracture),
and chronic local inflammatory conditions (e.g., peri-implant osteolysis) [119, 146148]. We posited that the mechanism for this passive targeting is different from
the enhanced permeability and retention (EPR) effect [149] and may be explained
by an ELVIS mechanism (Extravasation through Leaky Vasculature and Inflammatory cell-mediated Sequestration) [134, 150, 151], in which the systemically administered nanomedicine would extravasate through the leaky vasculature at the
inflammatory lesion and be sequestered locally via inflammatory cell infiltrates and
activated resident cell. Concurrently, for systemic inflammatory conditions, a fraction of the nanomedicine administered may also be sequestered by white blood
cells (WBC) in the circulation and be actively transported to the inflammatory lesion.
Previously, we have found that the HPMA copolymers’ structural parameters, such
as average MW and drug loading, have a significant impact on their pharmacokinetic and biodistribution (PK/BD) profile in a systemic inflammatory arthritis rat
model[144]. The focus of this and the next chapter, therefore, is to define the
impact of MW and drug loading on PK/BD profile of HPMA copolymer-dexamethasone conjugates in a model of localized inflammation. For this purpose, we synthesized a series of HPMA copolymers with different MW or Dex content as
described above. Using both 125I-labeling/gamma counter techniques and the NIR
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optical imaging, we would validate the impact of MW and Dex content on the
PK/BD profiles of HPMA copolymers in the mouse model of aseptic implant loosening in the following chapter.
Besides molecular weight and drug content, the chemical structure of the Dex
containing monomer will also affect the conjugates’ pharmacokinetics since it will
affect the drug releasing property. To better understand the influence of the polymer properties on the biology system, and to further instruct the future drug development, the designation and synthesis of polymers with different Dex containing
polymers were of high value. With a low drug loading of the P-Dex-B, it was excluded from the in vivo evaluation, with the consideration of the drug content shall
be similar when comparing with the other polymers to avoid multiple factors in the
same experiment. The results from in vivo therapeutic of those different monomers
containing polymers would be compared in this chapter and following chapters.
2.5 Conclusion
In this chapter, we designed and synthesized a series of the HPMA copolymers
with different structural parameters. The HPMA copolymers with different molecular weight (MW) and/or Dex contents were labeled using Alexa Flour® 488, IRDye
800 CW, and radio isotope

125I

respectively. Different Dex containing monomers

were designed, synthesized and polymerized with HPMA to form different HPMADex-copolymers with different Dex releasing rates. The conjugates were characterized for their molecular weight, polydispersity, labeling content, and in vitro releasing rate.
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CHAPTER 3
PK/BD ANALYSIS AND IN VITRO INTERNALIZATION ANALYSIS OF
MACROMOLECULAR PRODRUG WITH DIFFERENT MOLECULAR WEIGHT,
DRUG COTENT IN THE ASEPTIC IMPLANT LOOSENING MOUSE MODEL
3.1 Introduction
As discussed in Chapter 1, we would focus on elucidating the impact of different
structural parameters on HPMA copolymer conjugates’ PK/BD profile in an aseptic
orthopedic implant loosening mouse model. The results from the study of this
chapter will help identify the optimal structural design of the HPMA copolymerbased theranostic platform for early diagnosis and prophylactic treatment of periprosthetic osteolysis, respectively. We would try to develop a novel theranostic
strategy for early diagnosis and effective treatment of peri-implant orthopedic wear
particle-induced osteolysis by systematically manipulating the structural parameters of the system to optimize its extravasation/lymphatic clearance, cellular uptake,
partitioning and drug release using the novel intraosseous femoral implant mouse
model.
3.2 Materials and Methods
3.2.1 Materials
Ten-week-old male CD 1 IGS mice were purchased from Charles River Laboratories and maintained under standard housing conditions. All animal experiments
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were performed in accordance with protocols evaluated and approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska
Medical Center.
3.2.2 Instruments
Isoflurane vaporizer (Midmark Corp, Dayton, OH) was used to anesthetize animals during live imaging analyses. A Faxitron MX-20 Cabinet X-ray System (Faxitron Bioptics, Tucson, AZ) was used in the implant loosening model establishment
to confirm the implant position. A Packard Cobra II Gamma Counter (PerkinElmer,
Waltham, MA) was used in the tissue radioactivity counting in the gamma counterbased PK/BD study. A Pearl Impulse small animal imaging system (LI-COR, Lincoln, NE) was used for near-infrared (NIR) optical imaging of live animals. Flow
cytometry on disaggregated cells was performed on a BD LSRII flow cytometer
(BD Biosciences, San Jose, CA) and on BD FACS Scan and BD FACS Canto
cytometers for the in vitro uptake studies.
3.2.2 Establishment of a murine prosthesis failure model
A murine prosthesis failure model was established surgically as we described
previously [141]. Poly(methyl methacrylate) (PMMA) particles (1−10 μm, Bangs
Laboratories, Fishers, IN) were used to induce the peri-prosthetic inflammation.
The position of the implant was validated with Faxitron MX-20 Cabinet X-ray System. Mice were administrated antibiotics (cefazolin sodium, 20 mg/kg, s.c.) immediately after surgery, and analgesics (buprenorphine, 0.5 mg/kg, s.c.) were given
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twice daily for 3 days after surgery. Biweekly intraarticular injection of PMMA particles (1 mg in 10 μL sterile saline) into the left knee joint was done postoperatively
to mimic the gradual particle releasing process in the patients. Saline of similar
volume was injected into the right knee as the control. A total of 180 male CD 1
IGS mice were used in the gamma counter-based PK/BD analysis experiment, and
25 mice were used for the NIR imaging-based PK/BD analysis.
3.2.3 Gamma counter-based pharmacokinetic and biodistribution analysis
On 30th day post implant introduction,

125I-labeled

and unlabeled P-Dex-Tyr-

NH2 conjugates (∼1.5 μCi/mice, 5 mg polymer/mice) were mixed and administered
to mice (5 mice/group) via tail vein injection. Animals were sacrificed at designated
time points (0.5, 2, 6, 16, 48, 168 h). Blood and other major organs/tissues including, heart, lungs, kidneys, liver, spleen, and both hind limbs were isolated at euthanasia. They were processed and analyzed using a Packard Cobra II Gamma
Counter without perfusion. The pharmacokinetic parameters, such as total clearance (CL), the volume of distribution (Vd), and biological half-life (t1/2) were determined using the bolus intravenous input noncompartmental analysis of WinNonlin
(version 6.3, Pharsight, Mountain View, CA). The area under the curve (AUC) was
calculated using the trapezoidal rule. The relative exposure ratio was calculated
by dividing AUCtissue by AUCblood. AUClast from both tissues and blood was used for
the relative exposure ratio.

55

3.2.4 Near-infrared optical imaging analysis
On the 30th day post implant introduction, mice were given P-Dex- IRDye (0.3
mg/mice) via tail vein injection (5 mice/group). The mice were imaged at designated time points (0.5, 24, 48, 72, 96, 120, 144, 168 h) using a Pearl Impulse small
animal imaging system to evaluate the distribution and retention of the IRDye-labeled prodrug. All mice were anesthetized with 2% isoflurane throughout procedures and dehaired before imaging. Imaging acquisition condition is dual channel
(800 nm and white light) with 85 μm resolution. Images for each mouse were
normalized using the same intensity scale with a common minimum and maximum
value. The signal intensity from the left joints was semiquantitatively analyzed by
the resident software (Pearl Impulse Software). The regions of interest (ROI) with
identical areas were selected manually as a 59 × 59 (pixels) ellipse shape using a
drawing tool in the software at both knee joints and background (Figure 3.1). The
center of the ROI was located to the knee joint manually. Signal intensity of the
knee joint minus background signal intensity was then corrected for the area (pixels). Although the fluorescence dye content was controlled similar when synthesized, to compare with the signals from animals receiving different conjugates, a
signal standardization method was developed as follows: conjugate solutions (20
μL, 3 mg/mL) were dropped on a Petri dish and imaged at the same imaging conditions (Figure 3.1A). The signals from the droplets were analyzed using the same
method described above. The signal from the left knee joint was corrected according to the signal intensity obtained from conjugates droplets images in Figure 3.1A
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in order to eliminate the impact of different dye content in the conjugates during
the in vivo imaging analysis. The equation is listed below:

𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝑒𝑎𝑛 𝑆𝑖𝑔𝑛𝑎𝑙 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (%) =

𝐼𝐿 −𝐼𝐵
× 100%
𝐼𝑖 − 𝐼𝐵𝑖
× 5𝑚𝑔
20𝜇𝐿 × 3𝑚𝑔⁄𝑚𝐿

where IL is mean signal intensity from left knee ROI, IB is mean signal intensity
from background, Ii is mean signal intensity from initial droplet, and IBi is mean
signal intensity from background in initial droplet image.
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Figure 3.1 Near infrared imaging analysis of mice with systemic administration of
P-Dex-IRDye conjugates. A. Images of conjugate solution drops (20 µL, 3 g/mL).
The percentage represents the Dex content in each polymer conjugate tested. The
circled areas identify representative regions of the ROI and background selected
for analyses.
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3.2.5 Fluorescence-activated cell scanning (FACS) analysis
The FACS analysis procedure was adapted from previous work [118]. Two
days after the last intraarticular particle injection, the mice were given P-Dex-Alexa
488 (5 mg/mouse) via tail vein injection. At necropsy (24 h post injection), the left
femurs were isolated and minced aseptically. The tissues were further digested
with type IA collagenase (1 mg/mL, Sigma- Aldrich) at 37 °C for 30 min twice. After
passing through a 70 μm cell strainer, ACK Lysing Buffer (Quality Biological,
Gaithersburg, MD) was then used to remove the red blood cells. After centrifugation (1200 rpm, 5 min), a single cell suspension (1 × 106 cells/50 μL) was obtained.
For FACS evaluation of dendritic cells, macrophage, monocytes, and fibroblast
cells, the samples were incubated with the following antibodies: hamster antimouse CD11c (BD Biosciences, Pharmingen), Allophycocyanin (APC)-labeled rat
antimouse F4/80 (eBioscience, San Diego, CA), APC-labeled rat antimouse Ly6G (Gr-1, Gr1) (eBioscience, San Diego, CA), and Alexa Fluoro 647 labeled rabbit
antimouse P4HB (Abcam, Cambridge, MA), respectively, for 30 min on ice. Cells
incubated with hamster antimouse CD11c were further treated with Alexa Fluoro
647-labeled goat antihamster secondary antibody for another 30 min on ice. All
the cells were then fixed in FACS fixation buffer and stored at 4 °C prior to analyses
on a BD LSR II flow cytometer.
3.2.6 In Vitro internalization study of HPMA copolymer conjugates in macrophages.
To evaluate the internalization of HPMA copolymer conjugates in vitro, fluorescence microscopy and flow cytometry were used to conduct these studies.
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3.2.6.1 Fluorescence microscope imaging.
Primary BMMs were prepared by conventional procedures and plated onto
glass coverslips at a density of 2.5 × 105 cells per well of a 12-well plate in alphaMEM medium supplemented with 10% fetal bovine serum and 25 ng/mL M-CSF.
After overnight incubation, copolymers were added from a 20 mg/mL stock in PBS
to a final concentration of 40 μg/mL. After additional 24 or 48 h incubation, cells
were washed with HBSS, labeled with Hoechst 33342 (2 μg/mL for 5 min in HBSS),
fixed with 2% paraformaldehyde for 15 min at 37 °C, washed with HBSS, and
mounted using ProLong Gold Antifade mounting medium. Cells were imaged, and
captured images were analyzed using a Nikon Eclipse fluorescence microscope.
3.2.6.2 Flow cytometric analysis.
Primary BMMs were prepared by conventional procedures and plated in alphaMEM Petri dishes (one million cells in 8 mL per dish). After overnight incubation,
polymers were added from a 20 mg/mL stock in PBS to a final concentration of 40
μg/mL. After additional incubation 4−48 h, cells were washed with PBS, trypsinized, washed again, and resuspended in 0.6 mL of stain buffer (BD Pharmigen).
Cells were stained with a 7-AAD viability stain prior to flow cytometric analysis on
FACScan or FACScanto cytometers.
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3.3 Results
3.3.1 The pharmacokinetics and biodistribution of the HPMA copolymer conjugates in the peri-implant osteolysis mouse model
3.3.1.1 Gamma counter-based PK/BD analyses of HPMA copolymer conjugates
in the peri-implant osteolysis mouse model using 125I-labled conjugates
The percentage of injected conjugate dose per gram (ID/g) of tissue vs time
(0.5, 2, 6, 16, 48, and 168 h postinjection) in all major organs, blood, and both
femurs are shown in Figure 3.2. For P-Dex with different MWs but the same Dex
content (∼12 wt %), MW clearly had a major impact on the distribution of P-Dex
conjugates in major organs. Of all the conjugates tested, P-Dex-40 kDa-12%,
which has the highest MW, showed the maximum ID/g value in most of the organs
examined at the earliest time points. In the kidney, however, the conjugate with the
lowest MW (P-Dex-20 kDa-12%) was found with the highest ID/g values at the end
point. While all other conjugates examined exhibited a biphasic clearance pattern,
PDex-40 kDa-12%’s clearance showed a unique pattern. Increased ID/g values
were found for P-Dex-40 kDa-12% during 2−6 h postinjection in all tissue and organs, during 16−48 h in the liver and both femurs, and during 48−168 h in the
spleen. Increased ID/g values were also found in both femurs and spleen during
2−6 h postinjection with P-Dex-30 kDa-0%. In all organs and tissues, P-Dex-30
kDa-6% showed the lowest ID/g at every time point. The difference between the
PMMA particle-injected left femur and nonparticle-injected right femur were not
significant with all of the tested polymer conjugates, which is contrary to our previous findings [118].
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Figure 3.2 The pharmacokinetics profiles of HPMA copolymer conjugates with different molecular weights and Dex contents in blood and major organs/tissues over
the time course of 7 days post i.v. administration. n=5.

62

3.3.1.2

Biodistribution of HPMA copolymer conjugates in tissues according to

the live optical imaging
Due to the insensitivity of gamma counter-based PK/BD analysis techniques in
defining the differential distribution pattern of P-Dex conjugates between the femur
with peri-implant osteolysis and the control, we performed additional analyses using P-Dex conjugates labeled with IRDye 800CW. As shown in Figure 3.3, this
approach confirmed the critical role of MW in determining the PK/BD profile. The
retention time of the P-Dex in vivo increased with an increase in MW. Unlike the
gamma counter-based PK/BD study, live NIR optical imaging permitted discrimination of the peri-implant inflammation site from the control site. The fluorescent
signal intensity from left knee (with implant and particle infusion) increased with
the increase of MW at the same time point post i.v. administration. When the signal
from the knee joint was corrected as described in the equation in the methods
section, the semiquantitative results (Figure 3.5) corroborate well with the visual
observation. In Figure 3.4, the P-Dex-30 kDa-6% showed an unexpected PK/BD
profile, comparing with all the other groups. The fast elimination of the conjugate
was evidenced by the low signal from the mice after 48-h post-injection. This result
was in agreement with the gamma counter-based PK/BD experiment finding using
P-Dex-125I.
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Figure 3.3 Representative NIR optical images of mice with femur implants challenged with PMMA particles on left femur and PBS on the contralateral side. Images were obtained 0.5, 24, 48, 72, 96, 120, 144, and 168 h after one intravenous
injection of P-Dex-IRDye conjugates (Dex content ∼12 wt %, with different MW).
Pseudo color-coded signal intensity reflects the level of polymers within the mice.
The signal intensity was normalized using the same intensity scale for each image.
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Figure 3.4 Representative NIR optical images of mice with femur implants challenged with PMMA particles on left femur and PBS on the contralateral side. Images were obtained 0.5, 24, 48, 72, 96, 120, 144, and 168 h after one intravenous
injection of P-Dex (MW ~ 35 kDa, with different Dex content) at designed time
points. Pseudo color-coded signal intensity reflects the level of polymers within
the mice. The signal intensity was normalized using the same intensity scale for
each image.
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Figure 3.5 Semi-quantitative analysis of the image signals gained from optical image system.
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3.3.2 Gamma counter-based pharmacokinetic analyses
PK parameters of the tested conjugates in blood and major organs/tissues were
obtained using a noncompartmental analysis (Table 3.1). Systemic exposure as
expressed by AUC and MRT increased with increasing MW. For example, AUC of
PDex- 40 kDa-12% was ∼26-fold higher than P-Dex-20 kDa-12%. Both Vd and Cl
decreased with increasing MW, but the decrease in Cl was more pronounced,
which leads to the overall increase in exposure as measured by AUC and MRT.
Also the low Cl associated with higher MW formulation (P-Dex-40 kDa- 12%) led
to the longer half-life of 35.8 h. Increasing the MW increased exposure of blood,
as well as all other tissues as measured by AUC and MRT. Dex loading also affected the MRT and AUC. For example, P-Dex-30 kDa-0% had ∼3-fold higher
AUC0‑∞ than P-Dex-30 kDa-6%, and Cl of P-Dex-30 kDa-6% was ∼3-fold higher
than P-Dex-30 kDa-0%; while PDex-30 kDa-12% had ∼2-fold higher AUC0‑∞ than
P-Dex-30 kDa-6%, and Cl of P-Dex-30 kDa-6% was 2-fold higher than PDex- 30
kDa-12%.
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Parame-

P-Dex-20

P-Dex-30

P-Dex-40

P-Dex-30

P-Dex-30

ters (unit)

kDa-12%

kDa-12%

kDa-12%

kDa-6%

kDa-0%

t1/2 (hr)

27.4 ± 5.9

22.3 ± 6.6

35.8 ± 3.7

23.9 ± 3.5

24.3 ± 4.7

Cl

316.9 ±

115.7 ±

(mL/hr/kg)

19.1

10.6

6,473.5 ±

1,850.6 ±

516.4 ±

4,225.1 ±

1,332.2 ±

301.6

274.2

77.7

516.2

154.3

1,057,256.

10,134,744

4±

.0 ±

103135.1

732647.0

1.1 ± 0.5

1.3 ± 1.5

4.2 ± 1.4

0.6 ± 0.3

0.7 ± 0.4

0.34

0.38

0.23

0.43

0.39

0.33

0.35

0.23

0.49

0.41

0.67

0.71

0.49

0.74

0.64

1.43

1.1

0.8

1.36

0.84

0.64

0.52

0.42

0.45

0.43

238.6 ±
12.5 ± 0.9

73.9 ± 3.8
11.6

Vss(mL/kg)

AUC0-
376,071.8
(blood) (hr*

520,626.4

± 22102.0
count/gm)

1,682,399.
0±
± 24637.4
86933.0

AUC (%
extrapolation)
AUCleft femur/AUCbood

AUCright femur/AUCbood

AUCheart/A
UCbood
AUCliver
/AUCbood
AUCspleen/A
UCbood
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AUClungs/A
1.1

0.92

0.60

0.98

0.85

6.02

1.6

0.57

2.32

0.77

20.4 ± 0.6

16.1 ± 2.8

41.4 ± 5.9

17.7 ± 2.2

18.0 ± 1.3

2.94

3.57

2.58

3.74

4.34

2.97

3.54

2.44

3.43

4.33

2.64

3.36

2.03

3.29

3.30

4.06

4.09

2.38

3.83

3.68

4.54

4.21

2.43

3.37

3.83

2.88

4.29

1.70

3.08

3.85

2.42

3.06

1.70

2.94

2.93

UCbood
AUCkidney/AUCbood

MRT0-
(blood) (hr)
MRTleft femur/MRTbood

MRTright femur/MRTbood

MRTheart/M
RTbood
MRTliver
/MRTbood
MRTspleen/
MRTbood
MRTlungs/M
RTbood
MRTkidney/MRTbood
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Table 3.1 The pharmacokinetic (PK) parameters of different HPMA copolymer conjugates after systemic administration. t1/2, the half-life associated with the elimination phase; CL, total body clearance; Vss, volume of distribution in steady state;
AUC, area under a concentration of analyte vs time curve.
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3.3.3 In Vivo fluorescence-activated cell scanning (FACS) analysis
For all the tested cell phenotypes (CD11c+, F4/80+, Ly-6G (Gr-1, Gr1)+, and
P4HB+, see Figure 3.6), the percentage of cells that internalized the P-Dex copolymers increased with the increase of the MW of the polymers (e.g., PDex-15 kDa12%, P-Dex-35 kDa-12%, and P-Dex-45 kDa-12%). This increase was highly significant when the MW was raised from 15 to 35 kDa. For instance, the percentage
of CD11c positive cell increased from 41.67% to 89.28% when treated with P-Dex15 kDa-12% and P-Dex-35 kDa-12%, respectively. The difference in the percentage of the cells that internalized the polymers was not significant, however, when
MW was raised from 35 to 45 kDa. The Dex content also affected the cell uptake
of P-Dex copolymers. With the increase of Dex content, the percentage of the cells
that internalized the P-Dex copolymers was also increased for several of the cell
phenotypes tested in this study (see Table 3.2). As shown in Figure 3.7, over 90%
of the cell-sequestered P-Dex-Alexa were found in Ly-6G (Gr-1, Gr1) positive cells.
The cell uptake efficiency increased with the increases of P-Dex MW. The impact
the Dex content has on cell internalization efficiency was more complex. For example, more P-Dex with higher Dex content was sequestrated by F4/80 positive
cell, while more P-Dex with lower Dex content was sequestered by Ly-6G (Gr-1,
Gr1) positive cells (see Table 3.3).
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Figure 3.6 Percentage of different cell phenotypes isolated from peri-implant region
that internalized different HPMA copolymers-Dex conjugate. Except for those
noted as not significant (ns, P > 0.05), all the other paired group comparisons are
statistically significant (P < 0.05).

72

Figure 3.7 Percentage of P-Dex-Alexa internalized by different cell phenotypes
isolated from peri-implant region. Except for those noted as not significant (ns, P >
0.05), all the other paired group comparisons are statistically significant (P < 0.05).
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P-Dex-15

P-Dex-35

P-Dex-45

P-Dex-35

P-Dex-35

kDa-12%

kDa-12%

kDa-12%

kDa-6%

kDa-0%

CD11c+

41.67

89.28

81.98

62.63

57.53

F4/80+

34.01

83.85

80.09

65.22

64.19

Ly6G+

18.99

93.94

94.16

62.38

50.20

P4HB

38.61

81.75

72.79

54.008

57.77

Polymer

Table 3.2 The percentage of different cell phenotypes that internalized P-DexAlexa at the peri-implant region.
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P-Dex-15

P-Dex-35

P-Dex-45

P-Dex-35

P-Dex-35

kDa-12%

kDa-12%

kDa-12%

kDa-6%

kDa-0%

CD11c+

6.70

3.76

2.19

2.12

3.50

F4/80+

9.75

8.07

8.70

9.10

4.26

Ly6G+

97.07

96.26

91.40

98.61

98.45

P4HB

9.37

5.83

2.81

3.18

3.09

Polymer

Table 3.3 The percentage of P-Dex-Alexa being sequestered by different cell phenotypes at the peri-implant region.
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3.3.4 Impact of Structural Parameters on in Vitro BMM Internalization P-Dex.
To determine the effect of MW on cellular uptake of the HPMA copolymer conjugates, murine BMMs were incubated with Alexa-488 labeled P-Dex with Dex
content ∼12 wt % and different MW (ranging from 15 kDa to 45 kDa). Cells were
analyzed using flow cytometry and fluorescence microscopy at 4, 24, and 48 h
after addition of the copolymers to the cells. The flow cytometric data (Figure 3.8)
revealed that all four of these copolymers were taken up by the BMMs, being detectable at 4 h and increasing throughout the time course. MW did not appear to
have any significant effects on copolymer uptake since the kinetics and levels of
uptake were very similar between the four copolymers. To determine the effect of
Dex content on uptake of HPMA copolymers by BMMs, three copolymers of similar
MW (∼35 kDa), but differing Dex content were analyzed by flow cytometry and
fluorescence microscopy as described above.
Flow cytometry revealed that the kinetics and levels of uptake of the P-Dex 35
kDa-6 wt % and P-Dex 35 kDa-12 wt % conjugates were indistinguishable (Figures
3.9 and 3.10). Uptake of the dexamethasone-free copolymer appeared somewhat
higher than that of the dexamethasone-containing copolymers, which may in part
be due to the relatively higher loading of Alexa Fluor 488 on this copolymer.
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Figure 3.8 In vitro flow cytometry analysis of murine BMM internalization of P-Dex
with different molecular weight (Dex content ~12 wt %, labeled with Alexa Fluor
488).
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Figure 3.9 In vitro flow cytometry analysis of murine BMM internalization of P-Dex
with different Dex content (MW ~ 35 kDa, labeled with Alexa Fluor 488).
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Figure 3.10 In vitro fluorescence microscope analysis of murine BMM internalization of P-Dex (MW ~ 35 kDa, with different Dex content), 20×, scale bar = 50 μm.
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3.3.5 Dynamic Light Scattering Analysis of P-Dex
The dynamic light scattering analysis results of different P-Dex copolymers are
presented in Table 3.4 and results for P-Dex-35 kDa-6% at different concentration
can be seen in Table 3.5. The DLS data clearly suggests that P-Dex-35 kDa-6%
forms aggregates under the conditions tested. This finding may partially explain
the unexpected fast clearance of P-Dex-35 kDa-6% found in the PK/BD study.
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Sample

P-Dex-15

P-Dex-35

P-Dex-45

P-Dex-35

P-Dex-35

Name

kDa-12%

kDa-12%

kDa-12%

kDa-6%

kDa-0%

6.643

7.673

8.552

163.9

6.828

0.237

0.318

0.209

0.481

0.174

Z-Ave
(d.nm)
PDI

Table 3.4 Dynamic light scattering (DLS) analysis of copolymers at a concentration
of 5 mg/mL. Z-Ave: Z-Average size (diameter.nm); PDI: Polydispersity index.
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Concentration
5

37.5

150

Z-Ave (d.nm)

163.9

282.9

313.6

PDI

0.481

0.769

1

(mg/mL)

Table 3.5 Dynamic light scattering (DLS) analysis P-Dex-35 kDa-6% at different
concentration. Z-Ave: Z-Average size (diameter.nm); PDI: Polydispersity index.
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3.4 Discussion
As discussed in the chapter 2, the purpose of this chapter was to define the
impact of MW and drug loading on PK/BD profile of HPMA copolymer-dexamethasone conjugates in a model of localized inflammation. Thus, we conducted this
comprehensive comparison in a murine implant loosening model and obtained the
following finds.
3.4.1 Impact of Molecular Weight on PK/BD Profile.
MW clearly had a major impact on the PK/BD profiles of P-Dex conjugates in
the gamma counter-based analyses (Figure 3.2). There was greater uptake and
retention of the conjugates with the higher MWs in the major organs at every time
point evaluated, with the kidney as the only exception, which may be due to the
fact that the HPMA copolymer conjugates are known to be cleared through the
kidney, and the lower MW conjugates would be expected to have more rapid renal
clearance [79, 152, 153]. This was also reported in our previous finding when
analyzing the PK/BD profile of HPMA copolymer conjugates using inflammatory
arthritis rat model [144]. The %ID/g of most of the P-Dex conjugates in all the
organs and tissues decreased over time. In this analysis, we also found the

125I

activity (representing the amount of P-Dex) between the particle-injected left femur
and nonparticle-injected right femur was not significantly different, which was not
consistent with our previous findings [154, 155]. The systemic exposure of the
conjugate increased when the MW was raised. The AUC0-∞ (blood) of the conjugates positively correlated with the MW of the conjugates, and Cl of the polymers

83

was negatively correlated to the MW of the polymers. There is no significant difference between AUCleft femur/AUCbood and AUCright femur/ AUCbood for all the tested
polymer conjugates. Review of the protocol suggests that the discrepancy may be
attributed to the technical limitation of not being able to isolate the peri-implant
inflammatory tissue from the surrounding noninvolved tissues.
Instead, the whole leg was isolated without perfusion. Since the tissue samples
harvested were much larger than the peri-implant inflammatory lesion in this model,
the radioactivity associated with the large quantities of nonrelevant tissue may
have masked the small activity of the P-Dex-125I targeted to the peri-implant lesion,
leading to the inconclusive results. In order to overcome the limitation of the
gamma counter-based PK/BD analyses, we conducted a semiquantitative nearinfrared optical imaging-based PK/BD analysis to better recapitulate the passive
targeting of P-Dex to the peri-implant lesion. The methodology was successful in
establishing the preferential localization of the P-Dex in the particle-injected left
femurs, and this was true for all the polymer conjugates tested. Furthermore, as
evident in Figures 3.3 and 3.5, the increase of MW provided longer retention of the
polymers at the peri-implant inflammatory site and better differentiation of the left
(with particle infusion) and right (without particle infusion) legs. Also shown in Figure 6, there was a trend of increase of ROI signal intensity at 1-day postinjection
for both P-Dex-35 kDa-12% and P-Dex-45 kDa-12% groups. This may be due to
recirculation of the copolymers in the system [156].
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3.4.2. Impact of Drug Loading on the PK/BD Profile.
Based on the findings presented in Figures 3.2 and 3.4 and Table 3.1, higher
Dex content provided a higher systemic exposure and a longer retention of conjugates at the inflammatory site. An unexpected finding was that the P-Dex with ∼6
wt % Dex content exhibited unusually rapid elimination in both gamma counter
analysis and NIR optical imaging studies, which was not found in our previous work
using inflammatory arthritis rat model [144]. This experiment was repeated multiple times, and the results were confirmed. Further examination revealed that the
PBS or DD water solution of P-Dex-30 kDa-6% and P-Dex-35 kDa-6% was cloudy,
which suggested the potential of polymer aggregation in the solutions. DLS analyses of the P-Dex-35 kDa-6% in DD water confirmed the presence of aggregates,
and the aggregation size was positively correlated with the increase of the concentration. Compared to nonaggregating HPMA copolymers, the P-Dex-35 kDa-6%
aggregates (>150 nm even after dilution associated with systemic administration)
may be more rapidly internalized by the mononuclear phagocytic system (MPS),
leading to their enhanced clearance [157]. The gamma counter-based PK/BD
analysis, however, did not find high radioactivity in livers or spleens after P-Dex35 kDa-6% administration. The NIR optical imaging (Figure 3.4) seemed to support a very rapid renal clearance for the polymer. Clearly, the further investigations
are necessary to better understand the mechanism of the copolymer aggregation
and its rapid in vivo clearance.
To understand the impact of the P-Dex with different structural parameters on
cell uptake and sequestration in vitro, BMMs were treated with P-Dex of different
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MW and Dex content and analyzed at different time points for copolymer uptake
and sequestration by flow cytometry and fluorescence microscopy. The results of
these experiments revealed no significant differences in the kinetics or levels of
uptake between P-Dex of different MW or Dex content (which correlates with the
finding of others) [158], suggesting that cell autonomous mechanisms for copolymer uptake and sequestration operate independently of MW or Dex content. To
explore cellular uptake in the peri-implant tissue in vivo, Alexa Fluor 488 labeled
copolymers were given to mice. As shown in Figures 3.6 and 3.7 and Tables 3.2
and 3.3, the FACS analysis of the peri-implant tissue confirmed that all the copolymers were predominantly taken up by inflammatory myeloid cells (including inflammatory monocytes, macrophages, and dendritic cells), with a minor
component internalized by fibroblastic cells. For all cell populations analyzed,
there was a trend toward increased frequencies of cells internalizing copolymer
with increasing MW. In addition, the increase of Dex content also enhanced the
cell-mediated sequestration, especially for the CD11c+ cells. Since our in vitro cell
culture study suggested that the alteration of MW and Dex content would have
minimal impact on BMM internalization of the PDex, we speculate that the increased in vivo sequestration of PDex with higher MW polymers and/or higher Dex
content might be mainly attributed to their increased exposure to the cells as
demonstrated by their higher t1/2, AUC, MRT, and lower Cl. The results from this
comprehensive study are informative in assisting the future structural design of
HPMA copolymerbased theranostic system for early detection and prophylactic in-
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tervention of peri-implant osteolysis. Based on the findings of this study, we believe the use of a high MW (less than 45 kDa to ensure eventual renal clearance)
HPMA copolymer as the carrier for MRI, SPECT/CT, or PET/CT imaging modalities may provide the best early diagnostic tool. While this high MW would also
cause the imaging probe’s distribution to off-target anatomical locations, its potential risk of off-target toxicity is minimal due to its infrequent use and relatively low
dosing level. For therapeutic intervention, the data from the current study also
suggest that the use of a high MW (but less than 45 kDa to ensure eventual renal
clearance) HPMA copolymer as the drug carrier to ensure the optimal targeting to
the periimplant inflammatory lesion. The off-target distribution and associated toxicities, however, cannot be underestimated in this case. While our previous study
suggests the long-term use of P-Dex in managing peri-implant osteolysis may not
cause systemic osteopenia [119], its impact on other sensitive organs and tissues
(e.g., adrenal gland) is yet to be evaluated. If the safety profile of the HPMA copolymer−drug conjugate is not acceptable, a localized delivery strategy may be
considered as an alternative. Though the mechanism is not yet understood, the
finding of P-Dex aggregation at certain Dex content (6 wt %) must be carefully
evaluated when considering clinical translation of this potential macromolecular
prodrug conjugate, in order to ensure safety and a favorable PK/BD profile.
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3.5 Conclusion
Using gamma counter-based and optical imaging-based methodologies, we
evaluated the impact of structural parameters (i.e., molecular weight and drug content) on the pharmacokinetic and biodistribution (PK/BD) profiles of HPMA copolymer-dexamethasone

conjugates

in

an

aseptic

peri-implant

inflammation/osteolysis mouse model. The study found that the increase of both
the MW and Dex content facilitated targeting of P-Dex to sites of local inflammation
through increasing systemic exposure and reduced renal clearance of the conjugates. At certain level of Dex content (6 wt %), P-Dex may aggregate, leading to
a more rapid elimination of the copolymers from the system. Our findings will assist in the future design and development of HPMA copolymer-based theranostic
platform for early detection and therapeutic intervention of peri-implant osteolysis
and implant failure.
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CHAPTER 4
IN VIVO EVALUATION OF MACROMOLECULAR PRODRUG WITH DRUGCONTAINING MONOMERS THERAPEUTIC EFFICACY AND REDUCTION OF
TOXICITY
4.1 Introduction
As discussed in Chapter 1, drug releasing kinetic would have influence on the
drug therapeutic efficacy and toxicity reduction.
4.2 Materials and Methods
4.2.1 Instruments
Isoflurane vaporizer (Midmark Corp, Dayton, OH) was used to anesthetize animals during arthritis induction. Rats ankle diameter were measured using a digital
caliper (World Prescision Instruments, Inc., Saraspta, FL, USA). Bone quality were
analyzed using a Skyscan 1172 high resolution micro-CT system (Skyscan, Kontich, Belgium). A Faxitron® MX-20 Cabinet X-ray System (Tucson, Arizona, USA)
was used to monitor the hard tissue decalcification progress. A Leica RM2255
rotary microtome (Leica Biosystems Inc., Buffalo Grove, IL, USA) was used for
paraffin-embedded tissue sectioning.
4.2.2 The therapeutic evaluation of HPMA copolymers conjugates in adjuvant-induced arthritis rats
Male Lewis rats (175-200 g) obtained from Charles River Laboratories (Wilmington, MA, USA) were used to establish the adjuvant-induced arthritis (AA) rat
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model as described previously [146]. The rats were randomly divided into seven
groups: P-Dex-A, P-Dex-C, P-Dex-D, and P-Dex-E treatment (n = 7, single i.v.
injection on day 14 post-induction, dose equivalent of Dex = 10 mg/kg), Dexamethasone Sodium Phosphate treatment (n=7, equivalent of Dex = 10 mg/kg, divided
into 4 aliquots and injected on Day 14, 15, 16, 17), and saline control (n=4). An
additional group (n=4) of healthy rats were used as a negative control. Rats’ joint
edema and body weight were monitored daily from day 11. Blood was collected
for liver enzyme analysis at necropsy. All major organs and limbs were collected
at the euthanasia and fixed with buffered formalin before paraffin embedding at
day 44. All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Ne-braska Medical Center or Hospital for Special Surgery.
4.2.3 Observational assessment of AA rats’ joint inflammation
The articular index (AI) score was recorded during the treatment by the same
observers (XW and GZ) as described previously. An AI score was given to each
hind limb from day 11 to day 56 post-arthritis induction. The AI scoring system is
based on a 0-4 numeric system as the following: 0 = no signs of swell-ing or erythema; 1 = slight swelling and/or erythema; 2 = low-to-moderate edema and signs
involving the tarsals; 3 = pronounced edema with limited use of the joint and signs
extending to the metatarsals; 4 = excessive edema with joint ri-gidity and severe
signs involving the entire hind paw. The sum of the two hind limb scores for each
animal was recorded. Ankle diameter (medial to lateral) was measured using a
digital caliper as confirmation of inflammation-associated edema/hyperplasia.
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4.2.4 Micro-CT analysis of articular bone quality
Hind limbs were isolated after euthanasia and fixed with buffered formalin for
no less than 48 hr. The ankle joint bone quality was analyzed using a Skyscan
1172 micro-CT system. Micro-CT scanning parameters were set as fol-lows: voltage, 70 kV; current, 142 μA; exposure time, 1915 ms; resolution, 13.26 μm; with
aluminum filter (0.5 mm); rotation step = 0.4°; frame averaging = 4; random movement = 10; using 180° rotation scanning. Raw data were reconstructed using
NRecon to obtain a visual representation of the results, and the volume rendering
of the samples were performed via CTvox software (Skyscan). To quantitatively
compare the four treatments, the entire calcaneus and the selected region of interest (ROI) of the trabecular bone within the calcaneus were used as the anatomical sites for micro-CT analyses. The ROI was defined by aligning the calcaneus
bone along the sagittal plane using Data-viewer, with the ROI starts at the 75th
slide away from the epiphyseal plate and continues for 76 slides (1.98 mm). The
diameter of the cylindrical ROI was set at 1.00 mm. The morphometric parameters,
such as percent bone volume (BV/TV), bone surface density (BS/TV), trabecular
separation (Tb.Sp), trabecular number (Tb.N), bone mineral density (BMD), and
trabecular thickness (Tb.Th) were cal-culated using CTAn (Skyscan
4.2.5 Statistical methods
Two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test to
account for multiple comparisons, was used for data analysis using GraphPad
Prism Software. P-values ≤ 0.05 were considered statistically significant.
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4.3 Results
4.3.1 The polymers provides different pattern of sustained amelioration of joint inflammation in AA rats
Ankle diameter and AI score of the P-Dex-A, P-Dex-C, P-Dex-D, P-Dex-E, and
Dex treated group exhibited different outcome upon treatment. Dex treated group
showed an immediate recovery of the swelling, however, a dramatic flare upon
cessation of Dex treatment on day 19 (Figure 4.1). A single injection of Dex containing HPMA conjugates (dose equivalent to the Dex treatment) resulted in different level of reductions in ankle swelling and AI score from day 15 to 44. The ankle
diameter difference significance of different treatment group was summarized in
Table 4.1, Table 4.2 and Table 4.3 for the comprehensive comparison. The therapeutic efficacy difference was also in agreement of the in vitro releasing profiles
of the polymer conjugates (Figure 2.8).
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Figure 4.1 HPMA conjugates polymerized with different dexamethasone containing monomers showed different therapeutic effect on amelioration of joint inflammation in an adjuvant-induced arthritis (AA) rat model. (A) The change of AA
rats’ left ankle joint size of different groups during the treatment study; (B) The
change of articular index score of different groups during the treatment study. The
red arrow indicated the day when rats received the single conjugates injection and
the daily free Dex treatment was initiated. The green arrow indicated the day when
rats received their last free Dex treatment. The prevention of arthritic ankle swelling by single injection of P-Dex-E was sustained for about one month from day 15
to day 44.

94

P-Dex-A
vs.
P-Dex-C
P-Dex-A
vs.
P-Dex-D
P-Dex-A
vs.
P-Dex-E
P-Dex-A
vs.
Dex
P-Dex-A
vs.
Saline
P-Dex-A
vs.
Healthy
P-Dex-C
vs.
P-Dex-D
P-Dex-C
vs.
P-Dex-E
P-Dex-C
vs.
Dex
P-Dex-C
vs.
Saline
P-Dex-C
vs.
Healthy
P-Dex-D
vs.
P-Dex-E
P-Dex-D
vs.
Dex
P-Dex-D
vs.
Saline
P-Dex-D
vs.
Healthy

Day
0

Day
11

Day
12

Day
13

Day
14

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

*

ns

ns

ns

ns

ns

ns

ns

ns

ns

**

***

**

**

ns

ns

ns

ns

ns

**** **** **** **** ****

**

ns

ns

ns

ns

ns

ns

**

**

ns

Day
15

Day
16

Day
17

Day
18

Day
19

Day
20

Day
21

**** **** **** **** **** **** ****

ns

*

**

***

**

**** **** **** **** **** **** **** **** **** **** ****

ns

ns

ns

ns

ns

***

**** **** **** **** **** ****

ns

ns

ns

ns

ns

***

**** ****

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

**

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

*

**

*

**

ns

ns

**

ns

ns

***

**** **** **** **** **** **** ****

**** **** **** **** **** **** **** **** **** ****

ns

ns

**

**** **** **** ****

**** **** **** **** **** ****

*

ns

ns

ns

ns

ns

**

ns

**** **** **** **** **** **** **** **** **** **** ****

95
P-Dex-E
vs.
Dex
P-Dex-E
vs.
Saline
P-Dex-E
vs.
Healthy
Dex
vs.
Saline
Dex
vs.
Healthy
Saline
vs.
Healthy

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

**** **** **** ****

*

**

ns

ns

**** **** **** **** **** ****

**** **** **** **** **** **** **** **** **** **** ****

ns

ns

ns

ns

**** **** **** **** **** **** ****

ns

**** **** **** **** **** **** **** **** **** **** ****

ns

**** **** **** **** **** **** **** **** **** **** ****

Table 4.1 The statistical analyses of the joint diameter of the rats from different
treatment groups from Day 11 to Day 21 including the day of the adjuvant induction
Day 0. Two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test
to ac-count for multiple comparisons, was used for data analysis using GraphPad
Prism Software. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).
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Table 4.2 The statistical analyses of the joint diameter of the rats from different
treatment groups from Day 22 to Day 33 including the day of the adjuvant induction
Day 0. Two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test
to ac-count for multiple comparisons, was used for data analysis using GraphPad
Prism Software. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).
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Table 4.3 The statistical analyses of the joint diameter of the rats from different
treatment groups from Day 34 to Day 44 including the day of the adjuvant induction
Day 0. Two-way analysis of variance (ANOVA), followed by Tukey’s post hoc test
to ac-count for multiple comparisons, was used for data analysis using GraphPad
Prism Software. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).
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4.3.2 The polymers provides different protection of joint bone structure in AA rats
The most severe bone damage was found in the saline group, with extensive
erosion of the entire distal tibia. P-Dex-A, P-Dex-C, P-Dex-D, and P-Dex-E treated
animals demonstrated different level of reduced ankle bone erosion compared to
the saline group. One month following the single dose polymer administration,
there were only minor bone erosion found in P-Dex-A, P-Dex-C and P-Dex-E
treated groups. The quantitative analysis of the hind paw calcaneus trabecular
bone (Figure 4.2 A) micro-CT data showed that P-Dex-A, P-Dex-C and P-Dex-E
treatment preserved the bone quality at different level (different P value compared
with Saline control group), as is evident in the morphometric parameters, such as
percent BV/TV, BS/TV, Tb.Sp, Tb.N, BMD, and Tb.Th, with their values similar to
those observed for healthy controls, and significantly better than those observed
for the free Dex-treated. When the entire calcaneus bone was analyzed (Figure
4.2 B), the P-Dex-D, Dex and saline groups were found with significantly increased
calcaneus tissue volume, calcaneus total porosity and calcaneus bone surface and
significantly decreased calcaneus bone volume percentage, when compared to
the healthy and P-Dex-A, P-Dex-C and P-Dex-E treated groups.
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Figure 4.2 Micro-CT analyses of the hind paw of the rats from different treatment
groups. (B) Bone morphometric parameters of the trabecular bone ROI within calcaneus bone. (C) Bone morphometric parameters of the entire calcaneus bone. (*,
P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001).
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4.4 Discussion
The HPMA polymer conjugates polymerized with different Dex-containing monomers synthesized in Chapter 2 were validated the difference therapeutic efficacy
in this chapter. The adjuvant induced arthritis rats model were used for the proofof-concept. The amelioration of the rats’ ankles swelling which was measured
daily showed different trend in the rats received different treatment on day 14 postinduction. It was found that the drug releasing rates may have significant impact
on the drug therapeutic effect. For example, the significant joint amelioration of
the P-Dex-C and P-Dex-E treatment was found from the following day post-injection on Day 15 compared with Saline treated group. This significance between PDex-E and Saline was found until the animals were sacrificed. However, the significance between P-Dex-C and Saline groups showed smaller from Day 31 (from
P value <0.0001 to a higher P value), until Day 40 (26 days after injection) when
significance can hardly be found in joints diameter data. This phenomena correlated with the fast Dex releasing profile of P-Dex-C than P-Dex-E, which can offer
an immediate therapeutic effect but shorter sustention. This shorter sustention
may also lead to a less protection of the bone structure than P-Dex-E showed in
those Micro-CT data, such like trabecular bone percentage (Figure 4.2). When
comparing P-Dex-A and P-Dex-E therapeutic efficacy using Saline as a control
group, we could learn that the P-Dex-A treated animals started to show significant
reduced joints diameter from Day 16 (the third day after injection), which is slower
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than P-Dex-E, correlated with the Dex in vitro releasing profile that P-Dex-A released slower than P-Dex-E cannot offer as the same immediate anti-inflammatory
effect as P-Dex-E. The joints diameter reduction significance of of P-Dex-A treatment compared with Saline treatment showed smaller than that P-Dex-C and PDex-E compared with Saline (bigger or equal P value in the comparison between
P-Dex-A and Saline than it was between P-Dex-C and Saline or between P-DexE and Saline at the same day). In The fast releasing polymer (P-Dex-C) would
show the faster therapeutic action (Figure 4.1), however, would also show an obvious disease activity flare which may because the active ingredient (Dex) in the
macromolecular conjugates were less than its therapeutic concentration threshold.
Insufficient dosage may not only cause the disease flare in the fast releasing drug
treatment after a burst release, but also may cause the unobvious therapeutic outcome in the slow releasing treatment (P-Dex-D, which showed the slowest releasing rate in the pH 7.4). With the even slower releasing rate in the lysosomal acidic
condition (pH 5.0), P-Dex-D showed a slight better improvement of the ankle joint
protection than Saline treatment (joints’ diameter significant smaller than those of
Saline treated group on only Day 15, no significant bone structure protection was
found in micro-CT analyses compared with Saline group). This may be the consequence of that slow-releasing may not offer enough therapeutic active ingredient
at the inflammatory site. However, to different degree, the P-Dex-A and P-Dex-E
showed a sustained protection for the rats’ ankle. When approaching to the end
of this animal study, the ankles from the rats received P-Dex-E showed a trend to
start swelling, while the diameter of the ankles from the rats received P-Dex-A was
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still decreasing although it was not significant compared with Saline treatment
group because this animal model can self-recover. Considering in both pH7.4 and
pH 5.0, P-Dex-A showed slower releasing rates than P-Dex-E, the results from the
in vivo assessment was in agreement of the in vitro releasing study. P-Dex-E may
show a better therapeutic efficacy when comparing the treatment of P-Dex-A and
P-Dex-E at the same day post-treatment, at the same dosing level. However, to
further conclude if P-Dex-E or P-Dex-A was the better therapeutic would need
more evaluation on their effects on reduction the Dex side effect which may be
done in the future and a fully dose escalation comparison study.
4.5 Conclusion
We proved the therapeutic efficacy was highly related to the macromolecular
conjugates’ releasing kinetics. We also provided the chemical structure guidance
for the future drug designation for different releasing rate purpose of use.
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CHAPTER 5
DESIGN, SYNTHESIS AND CHARACTERIZATION OF MACROMOLECULAR
PRODRUG OF TOFACITINIB
5.1 Introduction
As an emerging class of medication, Janus kinase (JAK) inhibitors offer an alternative for RA patients who have experienced severe side effects or are refractory to current treatments. Tofacitinib (Tofa, CP-690 550), is a JAK inhibitor that
exhibits functional selectivity for JAK1/3 and JAK1/2 signaling pathways. It was
approved by the US Food and Drug Administration in 2012 for the treatment of
adults with moderate-to-severe RA who have had an inadequate response or who
are intolerant to methotrexate (MTX). Recent results from randomized clinical trials indicate that Tofa, used either as monotherapy [159-163] or in combination
[164-167] with MTX or other non-biologic disease-modifying anti-rheumatic drugs
(DMARDs) [168], leads to clinical improvement compared to placebo or MTX alone
in patients with moderate-to-severe RA.
As a potent suppressor of innate and adaptive immunity, Tofa has been associated with dose-dependent toxicity, including higher risk of infections, malignancy,
liver toxicity and hematologic abnormalities, which at least in part can be attributed
to its the ubiquitous biodistribution [169]. We hypothesized that the development
of a macromolecular prodrug of Tofa would modify its pharmacokinetics and biodistribution (PK/BD) pattern, favoring deposition in arthritic joints, which in turn
could widen the drug’s therapeutic window with sustained efficacy, providing the
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opportunity for future development of safer Tofa dosing regimens. To test this
hypothesis, a Tofa prodrug (P-Tofa) was synthesized by conjugating Tofa to a water-soluble, biocompatible N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer via a hydrolysable carbamate linker (Figure 5.1).
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Figure 5.1 A macromolecular prodrug of Tofacitinib (P-Tofa). (A) The synthesis of
HEMA-Tofa monomer; (B) The synthesis of P-Tofa.
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5.2 Materials and Methods
5.2.1 Materials
N-(2-Hydroxypropyl) methacrylamide (HPMA), S,S′-bis(α,α′-dimethyl-α″-acetic
acid)-trithiocarbonate,

and

N,N-dioctadecyl-N",N"-bis(2-hydroxyethyl)-1,3-pro-

panediamine (LA) were prepared as described in chapter 2. Tofacitinib and Tofacitinib citrate were purchased from JINLAN Pharm-Drugs Technology Co., Ltd
(Hangzhou, China). IRDye® 800CW carboxylate was purchased from LI-COR,
Inc. (Lincoln, NE, USA). Alexa Fluor® 647 NHS ester was purchased from Life
Technologies, Inc. (Eugene, OR, USA). All other reagents and solvents, if not
specified, were purchased from either Sigma-Aldrich (St. Louis, MO, USA) or
Acros Organics (Morris Plains, NJ, USA). All compounds were reagent grade and
used without further purification.
5.2.2 Instruments
1H

and 13C NMR spectra were recorded on a 500 MHz NMR spectrometer (Var-

ian, Palo Alto, CA, USA). The weight average molecular weight (Mw) and number
average molecular weight (Mn) of copolymers were determined by size exclusion
chromatography (SEC) using an ÄKTA FPLC system (GE HealthCare, Chicago,
IL) equipped with UV and RI (KNAUER, Berlin, Germany) detectors. SEC measurements were performed on a Superdex 200 column (HR 10/30) with phosphatebuffered saline (PBS, pH=7.4) as the eluent. HPMA homopolymer (PHPMA) samples with narrow polydispersity were used as calibration standards. HPLC analyses were performed on an Agilent 1100 HPLC system (Agilent Technologies, Inc.,
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Santa Clara, CA) with a Hypersil™ ODS C18 Columns (Thermo Scientific, Waltham, MA).
5.2.3 Synthesis of methacryloxyethyl chloroformate (HEMA-COCl)
Triphosgene (1710 mg, 5.7 mmol) in dichloromethane (4 mL, anhydrous) was
added dropwise into a solution of hydroxyethyl methacrylate (HEMA, 500 mg, 3.8
mmol) and triethylamine (390 mg, 3.8 mmol) in dichloromethane (6 mL, anhydrous)
maintained in an ice bath. The resulting mixture was stirred in the ice bath for 1 hr
and then at room temperature for 1 hr. After removal of the solvent and excess
phosgene using a rotary evaporator, the resultant white residue was extracted with
dry ether (5 mL). The solid was filtered and the filtrate was concentrated to give
HEMA chloroformate as colorless oil (715 mg, 96% yield).
1H

NMR (500 MHz, CDCl3): δ = 6.16 (m, 1H, =CH2), 5.64 (m, 1H, =CH2), 4.56

(t, J = 4.5 Hz, 2H, -CH2-), 4.42 (t, J = 4.5 Hz, 2H, -CH2-), 1.96 (s, 3H, -CH3);

13C

NMR (125.7 MHz, CDCl3): δ = 166.89 (O-C=O), 150.86 (Cl-C=O), 135.59 (=C),
126.62 (=CH2), 69.02 (-CH2-), 61.51 (-CH2-), 18.21 (-CH3).
5.2.4 Synthesis of Tofa-containing monomer (HEMA-Tofa)
HEMA-COCl (370 mg, 1.92 mmol) in dichloromethane (5 mL, anhydrous) was
added dropwise into a solution of Tofa (500 mg, 1.60 mmol) and diisopropylethylamine (DIPEA, 310 mg, 2.40 mmol) in dichloromethane (15 mL, anhydrous) maintained in an ice bath. The reaction mixture was stirred in the ice bath for 1 hr before
quenching with water (10 mL). The organic layer was separated and washed with
brine, then dried over anhydrous magnesium sulfate. After removal of the solvent,
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the resulting light-yellow residue was subjected to flash column chromatography
(CH2Cl2:CH3OH = 20:1) to afford the monomer as a white solid (715 mg, 95% yield).
1H

NMR (500 MHz, CDCl3): δ = 8.44 and 8.42 (s, 1H), 7.41 and 7.40 (d, J = 4.2

Hz, 1H), 6.64 and 6.58 (d, J = 4.2 Hz, 1H), 6.16 (s, 1H), 5.60 (s, 1H), 5.08 (br, 1H),
4.71 (t, J = 3.6 Hz, 2H), 4.54 (t, J = 3.6 Hz, 2H), 4.05 (dd, J1 = 13.2, J2 = 4.2 Hz,
0.5H), 4.07-3.45 (m, 6.5H), 3.33 (s, 3H), 2.51 and 2.46 (p, J = 6.1, 1H), 1.94 and
1.96 (s, 3H), 1.89-1.85 (m, 1H), 1.76-1.66 (m, 1H), 1.09 and 1.06 (d, J = 7.1 Hz,
3H);

13C

NMR (125.7 MHz, CDCl3): δ = 167.05 (O-C=O), 160.82, 160.38, 157.61,

157.52, 153.04, 153.01, 148.87 (N-C=O), 135.78, 126.36, 126.24, 121.60, 121.44,
114.33, 114.12, 106.21, 105.99, 105.17, 65.16, 65.06, 62.20, 61.98, 53.86, 53.58,
46.71, 43.74, 42.76, 39.48, 35.21, 34.75, 31.48, 31.22, 29.66, 25.20, 25.15, 18.25,
18.29 (CH3), 14.25, 14.10. ESI-MS: [M+H]+ = 468.8.
5.2.5 Synthesis of HPMA copolymer-Tofa conjugate (P-Tofa) via RAFT copolymerization
HPMA (3712 mg, 22.47 mmol) and HEMA-Tofa (750 mg, 1.60 mmol) were dissolved in anhydrous dimethyl sulfoxide (DMSO, 21 mL) with 2,2′-azobisisobutyronitrile (AIBN, 37.7 mg, 0.17 mmol) as initiator and S,S′-bis(α, α′-dimethyl-α″acetic acid)-trithiocarbonate (CTA, 33.7mg, 0.13 mmol) as the RAFT agent. The
solution was purged with argon and polymerized at 60 °C for 40 hr. The resulting
polymer was first purified by precipitation in acetone/diethyl ether (v/v = 1:1, 200
mL) twice to remove the unreacted low molecular weight compounds, and then
dialyzed against ddH2O. The molecular weight cutoff size of the dialysis tubing
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was 25 kDa of globular protein. The resulting solution was then lyophilized to afford the final P-Tofa (4.21 g).
To quantify Tofa loading, P-Tofa (1 mg/mL) was hydrolyzed in 0.01 N NaOH in
CH3OH overnight. The resulting solution was neutralized and analyzed with HPLC
(mobile phase: acetonitrile/water = 3/1; detection, UV 284 nm; flow rate = 1 mL/min;
injection volume = 20 μL). The analyses were performed in triplicate. The mean
value and standard deviation were obtained with Microsoft Excel.
5.2.6 The synthesis of P-Tofa-APMA
To introduce fluorescent labels to the P-Tofa for biodistribution and immunofluorescence analysis, primary amine was introduced into P-Tofa using the following
procedure: HPMA (700 mg, 4.89 mmol) and HEMA-Tofa (142 mg, 0.3 mmol) were
dissolved in anhydrous dimethyl sulfoxide (DMSO, 6 mL), N-(3-aminopropyl) methacrylamide hydrochloride (APMA, 9.5 mg, 0.05 mmol), 2,2′-azobisisobutyronitrile
(AIBN, 7.11 mg, 0.04 mmol) as initiator and S,S′-bis(α, α′-dimethyl-α″-acetic acid)trithiocarbonate (CTA, 6.79mg, 0.02 mmol) as the RAFT agent, placed in an ampule, and purged with argon and polymerized at 60 °C for 40 hr. The resulting
polymer was first purified by precipitation in acetone/diethyl ether (v/v = 1:1, 200
mL) twice to remove the unreacted low molecular weight compounds, and then
dialyzed against ddH2O. The amine content of the copolymer was determined as
3.56×10-5 mol/g using the ninhydrin assay.
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5.2.7 The synthesis of P-Tofa-IRDye
To monitor its distribution after systemic administration, P-Tofa was labeled
with IRDye® 800CW. The labeling procedure is briefly described as follows:
IRDye® 800CW carboxylate (1.25 mg, 1.1 µmol), N-(3-dimethylaminopropyl)-N’ethylcarbodiimide hydrochloride (EDC, 1.56 mg, 8.1 mmol) and hydroxybenzotriazole (HOBt, 0.49 mg, 3.6 mmol) were dissolved in N,N-dimethylformamide (DMF,
1 mL) in dark at 21 C and stirred for 30 min. DIPEA (7 mg, 0.054 mmol) and PTofa-APMA (50 mg, [NH2] = 1.78 µmol) in DMF (1 mL) were added into the reaction
mixture and then stirred overnight. The reaction solution was dialyzed to remove
DMF and low molecular weight reactants. P-Tofa-IRDye was then obtained via
lyophilization with [IRDye® 800CW] = 6.88 ×10-6 mol/g of the conjugate.
5.2.8 The synthesis of P-Tofa-Alexa
To monitor the cellular sequestration of the P-Tofa in the rat after systemic administration, P-Tofa was labeled with Alexa Fluor® 647. The labeling procedure is
briefly described as follows: Alexa Fluor™ 647 NHS Ester (1 mg, 0.8 µmol), DIPEA
(3.5 mg, 0.027 mmol) and P-Tofa-APMA (50 mg, [NH2] = 1.78 µmol) were dissolved in N,N-dimethylformamide (DMF, 1 mL) in dark at 21 C and stirred overnight. The reaction solution was dialyzed to remove DMF and low molecular
weight reactants. P-Tofa-IRDye was then obtained via lyophilization with [50] =
5.62×10-6 mmol/g of the conjugate.
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5.2.9 In vitro Tofa release from P-Tofa
P-Tofa conjugates (~ 3 mg) were dissolved in 5 mL of buffer solutions with 0.2%
sodium dodecyl sulfate (SDS, to create the “sink” condition) and different pH values (pH=7.4, pH=5.5, pH =10), and rats’ serum (Invitrogen). The release experiments were conducted in a shaking water bath (37 °C, shaking rate 20 rpm).
Hydrolysis samples (400 µL) were withdrawn at designated time points. The released Tofa was extracted with ethyl acetate (1200 µL), with a recovery rate at
94.3±0.48%. The solution of Tofa (300 µL) was subsequently dried using a centrifugal evaporator. The sample was then stored at -80 °C for HPLC analysis as
described above.
5.3 Results
5.3.1 Characterization of P-Tofa
P-Tofa has a weight average molecular weight (Mw) of 30.4 kDa, a number
average molecular weight (Mn) of 23 kDa and a polydispersity index (PDI) of 1.32,
representing a narrow polydispersity. The Tofa drug loading in P-Tofa was found
to be ~ 13 wt%. The in vitro Tofa release rate was found to be highly dependent
upon buffer pH values (Figure 5.2). Both acidic and basic pH environments accelerated Tofa release, when compared to the release rate at pH 7.4. The presence
of serum proteins in the releasing medium was also found to increase the Tofa
release rate. Under each condition tested, intact Tofa was gradually released from
P-Tofa. Interestingly, Tofa degradation was observed over time in the basic buffer
(pH 10), which is in agreement with previous findings [170]. During the course of
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the experiment (20 days), the release rates of Tofa from P-Tofa at pH = 5.5 and
7.4, in the rat serum averaged at ~1.5%, 2% and 2.5% of the loaded drug per day,
respectively.

Figure 5.2 In vitro Tofa release from P-Tofa at pH = 5.0, 7.4, 10.0 and in rat serum.
The mean values and standard deviation were calculated with GraphPad Prism, n
= 3.
5.4 Discussion
In recent years, significant progress has been made in understanding the essential role of specific proinflammatory cytokines and other immunological processes responsible for RA initiation and progression [17, 171].

Subsequent
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studies showed that the receptors for several proinflammatory cytokines exert their
effects through the activation of intracellular signaling pathways mediated by a
unique family of Janus kinases that phosphorylate downstream molecular targets
that control key inflammatory and immunological processes [172, 173]. This led
to the development of Tofacitinib (Tofa, CP-690 550), the first selective JAK inhibitor tested in humans. Tofa inhibits both JAK3 and JAK1, to a lesser extent JAK2,
and was found to be effective in disease suppression in a variety of clinical conditions and experimental models ranging from inflammatory arthritis, autoimmune
disorders and transplantation. A major challenge in the development of JAK inhibitors for the treatment of inflammatory and autoimmune disorders has been their
ubiquitous expression in multiple tissues and cell types, and the broad range of
biological activities that they control. Thus, despite demonstrated efficacy in RA,
their systemic administration is associated with many serious and potentially life
threatening adverse side effects, including infections, malignancy, liver toxicity and
hematologic abnormalities [169]. We hypothesized that selective targeting of Tofa
to sites of joint inflammation might substantially enlarge the therapeutic window of
Tofa, with the potential for an improved safety profile. We have previously shown
in animal models that the macromolecularization of glucocorticoids significantly
potentiates their therapeutic efficacy and reduces systemic toxicities [146, 147,
174, 175], via a unique targeting pattern of macromolecular prodrugs based on the
ELVIS mechanism (Extravasation through Leaky Vasculature and Inflammatory
cell-mediated Sequestration), in which the systemically administered prodrug ex-
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travasates through the leaky vasculature at the inflammatory lesion and is sequestered locally via inflammatory cell infiltrates and activated resident cells [134]. Concurrently, for systemic inflammatory conditions, a fraction of the nanomedicine
administered may also be sequestered by circulating white blood cells (WBC) and
be actively transported to the inflammatory lesion.
Based upon these previous studies, we hypothesized that a macromolecular
Tofacitinib prodrug would selectively target inflamed joints, followed by sequestration in resident cells and activation to release Tofa locally to suppress joint inflammation. Our initial attempt to conjugate Tofa to HPMA copolymer was challenging.
The secondary amine in the pyrrole ring is the only available site for chemical conjugation. Given the regional pyrrole/pyrimidine-conjugation, this amine is not very
reactive. Attempts to conjugate Tofa to HPMA copolymer via peptides or citraconic
acid linkers failed. Eventually, Tofa was successfully conjugated to HEMA via a
carbamate bond and the Tofa-containing monomer was copolymerized with HPMA
(Figure 5.1A and 5.1B). We purposely set the P-Tofa molecular weight (~ 30 kDa)
lower than the glomerular filtration threshold of 45 kDa of HPMA copolymer to allow
eventual renal clearance of the prodrug. There was an initial concern regarding
the use of a carbamate linker as it has been known to be relatively stable in vivo.
The in vitro release study (Figure 5.2), however, provided strong evidence that the
prodrug can be gradually activated under acidic environments (e.g. inflammatory
acidosis or lysosomal pH).
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5.5 Conclusion
In this study, we have developed a macromolecular prodrug of a Janus Kinase
(JAK) inhibitor, Tofacitinib (P-Tofa) using a well-established, water-soluble and biocompatible N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer.
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CHAPTER 6
IN VITRO AND IN VIVO EVALUATION OF TOFACITINIB PRODRUG
THERAPEUTIC EFFICACY AND REDUCTION OF TOXICITY
6.1 Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory disorder that affects up to
1% of adults worldwide [176, 177]. The disease often leads to significant pain
associated with progressive articular damage. At present, there is no cure for RA
[9, 178]. The identification of the key role of intracellular kinase signaling pathways
in the regulation of proinflammatory cytokines and immune cell activation has led
to the recent development of orally available low molecular weight drugs that selectively target individual members of the Janus kinase pathway [172].
As discussed in Chapter 5, we successfully synthesized Tofa prodrug (P-Tofa).
To further investigate this prodrug, the therapeutic efficacy and potential toxicities
of P-Tofa were evaluated in an adjuvant-induced arthritis (AA) rat model.
6.2 Materials and Methods
6.2.1 Instruments
Histology slides were scanned with a VENTANA iScanner HT (Tucson, AZ,
USA). Bone quality were analyzed using a Skyscan 1172 high resolution microCT system (Skyscan, Kontich, Belgium). A Faxitron® MX-20 Cabinet X-ray System
(Tucson, Arizona, USA) was used to monitor the hard tissue decalcification progress. A Leica RM2255 rotary microtome (Leica Biosystems Inc., Buffalo Grove,
IL, USA) was used for paraffin-embedded tissue sectioning. Tissue slides were
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analyzed using a ZEISS LSM 800 confocal microscope (Carl Zeiss Microscopy,
LLC, Peabody, MA, USA). Live animals were imaged using Xenogen IVIS® Spectrum in vivo imaging system (PerkinElmer Inc., Waltham, MA, USA).
6.2.2 Treatment of adjuvant-induced arthritis (AA) rats
As described previously [146], male Lewis rats (175-200 g) from Charles River
Laboratories (Wilmington, MA, USA) were used to establish the adjuvant-induced
arthritis (AA) rat model. The established AA rats were then divided into 3 groups:
P-Tofa treatment (n = 10, single i.v. injection on day 14 post-induction, dose equivalent of Tofa = 130.2 mg/kg), Tofa treatment (n=10, Tofa was suspended in 0.5%
methylcellulose/0.025% Tween 20 (Sigma), once daily oral gavage for 21 days
from day 14 post-induction, 6.2 mg/kg/day) [179], and saline control (n=8). An
additional group (n=5) of healthy rats were used as a negative control. Joint inflammation and body weight were monitored daily from day 11. Hematology profiles including absolute count of white blood cells (WBC), neutrophils (NE),
lymphocytes (LY), monocytes (MO), eosinophils (EO) and basophils (BA) were
analyzed using an HEMAVET 950 FS Hematology System (Drew Scientific Inc.,
Miami Lakes, FL, USA) every week post treatment initiation until the last date of
free Tofa treatment. Blood was collected for liver enzyme analysis at necropsy.
Liver function including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) were analyzed using a DTX 880 Multimode Detector (Beckman Coulter, Jersey City, NJ, USA) at UNMC clinical test
lab. All major organs were collected at the euthanasia and fixed with buffered
formalin before paraffin embedding. Tissue sections (5 μm) were processed and
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H&E stained for histological evaluation by a pathologist (SML), who was blinded
to the treatment group arrangement. All animal experiments were performed in
accordance with protocols approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Nebraska Medical Center or Hospital for
Special Surgery.
6.2.3 Observational assessment of AA rats’ joint inflammation
The articular index (AI) score was recorded during the treatment by the same
observers (XW and GZ) as described previously [146]. An AI score was given to
each hind limb from day 11 to day 56 post-arthritis induction. The AI scoring system is based on a 0-4 numeric system as the following: 0 = no signs of swelling or
erythema; 1 = slight swelling and/or erythema; 2 = low-to-moderate edema and
signs involving the tarsals; 3 = pronounced edema with limited use of the joint and
signs extending to the metatarsals; 4 = excessive edema with joint rigidity and
severe signs involving the entire hind paw. The sum of the two hind limb scores
for each animal was recorded. Ankle diameter (medial to lateral) was measured
using a digital caliper as confirmation of inflammation-associated edema/hyperplasia.
6.2.4 Micro-CT analysis of articular bone quality
Hind limbs were isolated after euthanasia and fixed with buffered formalin for
no less than 48 hr. The left ankle joint bone quality was analyzed using a Skyscan
1172 micro-CT system. Micro-CT scanning parameters were set as follows: voltage, 70 kV; current, 142 μA; exposure time, 3650 ms; resolution, 13.1 μm; with
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aluminum filter (0.5 mm); rotation step = 0.4; frame averaging = 6; random movement = 10; using 360 rotation scanning. Raw data were reconstructed using
NRecon to obtain a visual representation of the results, and the volume rendering
of the samples were performed via CTvox software (Skyscan). To quantitatively
compare the four treatments, the entire calcaneus and the selected region of interest (ROI) of the trabecular bone within the calcaneus (Figure 6.1) were used as
the anatomical sites for micro-CT analyses. The ROI was defined by aligning the
calcaneus bone along the sagittal plane using Dataviewer, with the ROI starts at
the 75th slide away from the epiphyseal plate and continues for 76 slides (1.98 mm).
The diameter of the cylindrical ROI was set at 1.00 mm. The morphometric parameters, such as percent bone volume (BV/TV), bone surface density (BS/TV),
trabecular separation (Tb.Sp), trabecular number (Tb.N), bone mineral density
(BMD), and trabecular thickness (Tb.Th) were calculated using CTAn (Skyscan).
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Figure 6.1 Region of interest in micro-CT analyses. Gray color: rat calcaneus bone;
Red color: cylindrical ROI within the calcaneus bone.
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6.2.5 Joint tissue histological evaluation
Right hind limbs were decalcified using 5% formic acid after fixation for histological analyses. Upon complete decalcification, the tissues were paraffin-embedded, sectioned (8 μm) approximately 200 μm apart, then H&E and Safranin O
stained. Stained sections were histologically graded by a pathologist (SML), who
was blinded to treatment groups [146], and then scanned using a high-throughput
bright-field slide scanner. Each histopathologic feature was graded as follows:
synovial cell lining hyperplasia (0 to 2); pannus formation (0 to 3); mononuclear
cell infiltration (0 to 3); polymorphonuclear leukocytes infiltration in periarticular soft
tissue (0 to 3); cellular infiltration and bone erosion at the distal tibia (0 to 3); and
cellular infiltration of cartilage (0 to 2). Scores for all of the histopathologic features
were summed for each animal.
6.2.6 P-Tofa biodistribution
P-Tofa was labeled with IRDye® 800CW (P-Tofa-IRDye) and administered i.v.
to AA rats (n=5) on day 14 post-induction. Rats were then imaged with a Xenogen
IVIS® Spectrum in vivo system under anesthesia at designated time points. The
images were captured with the following conditions: Excitation: 778 nm (Filter: 745
nm); Emission: 794 nm (Filter: 800nm); exposure times: 2 s; Field of View: 24.5
cm; Binning Factor: 8; f Number: 2. The captured images were then analyzed
using the Living Image 4.5 software (PerkinElmer Inc.). For ex vivo organ distribution analyses, P-Tofa-IRDye was administered i.v. to AA rats (n=3 per time point)
on day 14 post-induction. Rats were perfused and euthanized at the designated
time points. Major organs were then collected and imaged using a Pearl® Impulse
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small animal imaging system (LI-COR, Lincoln, NE, USA). The image acquiring
conditions were set as dual channels (800 nm and white light) with 85 µm resolution. The images for each rat were obtained using the same intensity scale with a
common minimum and maximum value.
6.2.7 Immunohistochemically analysis of P-Tofa’s cellular uptake within ankle
joints
Alexa Fluor® 647-labeled P-Tofa (P-Tofa-Alexa) was administered i.v. to AA
rats (n=5) on day 14 post-induction. Twenty-four hours later, rats were perfused
and euthanized. Hind limbs were collected, fixed and decalcified using 14% EDTA
solution (pH=7.4), paraffin embedded, sectioned (20 µm). The slides were immunohistochemically stained with the following antibodies: mouse anti-rat CD68
(Bio-Rad, MCA341R, dilution 1:100) and rabbit anti-rat P4HB (Abcam, ab85564,
dilution 1:50), respectively, overnight at 4 C after antigen retrieval using sodium
citrate buffer and blocked using 10% normal goat serum. Slides incubated with
mouse anti-rat CD68 were further incubated with Alexa Fluor 488-labeled goat
anti-mouse secondary antibody (Thermo Fisher scientific, A11001, dilution 1:1000)
and slides incubated with rabbit anti-rat P4HB were incubated with Alexa Fluor
488-labled goat anti-rabbit secondary antibody (Thermo Fisher scientific, A11008,
dilution 1:1000) for another 1 hr at 21 C in the dark. The stained slides were
imaged using a ZEISS LSM 800 confocal microscope after mounted in ProLong ®
Gold antifade mountant with DAPI (Thermo Fisher scientific, P36931, Waltham,
MA).
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6.2.8 In vitro macrophage cell culture.
Primary bone marrow macrophages (BMMs) were isolated from 6-8 week old
C57BL/6 mice [180]. BMMs were treated with Tofa (1 µM) or P-Tofa (Tofa equivalent = 16.1 µM) for 1 hr, after which 0.04 ng/mL, and 0.2 ng/mL of IL-4 was added
for 24 hr. For “washout” experiments, a similar procedure was followed, except
the P-Tofa/Tofa incubation time was increased to 24 hr, following which the cells
were washed and incubated with fresh medium (without P-Tofa or Tofa) for 72 hr
or 1 week, prior to the IL-4 challenge. RNA was isolated using RNAeasy kits (Qiagen, Redwood City, CA), in accordance with manufacturer’s recommendations
and reverse transcribed using the Maxima First Strand cDNA Synthesis Kit for RTqPCR (Thermo Scientific, Waltham, MA, USA). Real-time qPCR was performed
using the Maxima SYBR Green/Fluorescein qPCR Master Mix 2X (Thermo Scientific, Waltham, MA, USA) on a CFX96 real time thermocycler (Bio-Rad, Hercules,
CA, USA) and the relative gene expression was measured using the standard
ΔΔCq method and normalized to mouse GAPDH expression. Arg1, Ym1/2 and
Fizz1 and their respective sequences are listed as follows:
Arg1 (GGAATCTGCATGGGCAACCTGTGT/AGGGTCTACGTCTCGCAAGCCA),
Ym1/2 (GGGCATACCTTTATCCTGAG/CCACTGAAGTCATCCATGTC),
Fizz1 (TCCCAGTGAATACTGATGAGA/CCACTCTGGATCTCCCAAGA),
GAPDH (GGTGCTGAGTATGTCGTGGA/GTGGTTCACACCCATCACAA)
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6.2.9 Serum cytokine measurements
CXCL10 protein levels in rat serum samples collected weekly from day 14 to
day 56 were quantified by ELISA (Abnova, Rat CXCL10 ELISA Cat #KA2203, Taipei City, Taiwan). The assay was performed in duplicate using a two-fold dilution
of serum according to the manufacturer’s instruction.
6.2.10 Statistical methods
One-way analysis of variance (ANOVA), followed by Tukey’s post hoc test to
account for multiple comparisons, was used for data analysis using GraphPad
Prism Software. P-values ≤ 0.05 were considered statistically significant.
6.3 Results
6.3.1 P-Tofa provides sustained amelioration of joint inflammation in AA rats.
Ankle diameter and AI score of the Tofa-treated group exhibited a continuous
decrease from day 15 to 34 post-arthritis induction, with an immediate flare upon
cessation of oral Tofa on day 35 (Figure 6.2). A single injection of P-Tofa (dose
equivalent to the entire Tofa treatment) resulted in greater reductions in ankle
swelling and AI score from day 15 to 34, a difference that persisted to day 56. The
ankle diameter of the P-Tofa group was significantly lower (P < 0.05) than both the
Tofa group and saline group from day 14 to day 56; and significantly higher (P <
0.05) than the healthy control group from day 11 to day 56. No significant differences were found between the Tofa and saline groups except day 16 to day 22.
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Figure 6.2 P-Tofa can effectively amelioration of joint inflammation in an adjuvantinduced arthritis (AA) rat model. (A) The change of AA rats’ left ankle joint size of
different groups during the treatment study; (B) The change of articular index score
of different groups during the treatment study. The arrow pointing up indicates the
day when rats received the single P-Tofa injection and the daily oral Tofa treatment
was initiated. The arrow pointing down indicates the day when rats received their
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last oral Tofa treatment. The prevention of arthritic ankle swelling by single injection of P-Tofa was sustained for 6 weeks from day 15 to day 56.
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6.3.2 Histological Analysis of the Ankle Joints.
Compared to healthy control animals, histological analyses revealed marked
bone and cartilage destruction of the distal tibia, calcaneus and talus joints in the
saline-treated group, with periosteal expansion and inflammatory cell infiltration.
The Tofa-treated group exhibited histological findings similar to the saline group,
consistent with a limited capacity in preventing joint bone erosion and cartilage
damage. The single dose P-Tofa group, however, displayed markedly reduced
joint damage and cellular infiltration, with bone and cartilage morphology maintained similar to that of the healthy rats (Figure 6.3A, 6.3B). The sum of the score
from each animal was recorded and shown in Figure 6.3C. The statistically significant difference was found between Healthy vs. Saline, Saline vs. P-Tofa and PTofa vs. Tofa groups. No significant difference was found between P-Tofa vs.
Healthy or Saline vs. Tofa groups.
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Figure 6.3 Histology evaluation of Tofa and P-Tofa therapeutic efficacy. (A) H&Estained joint sections (10× and 40×). Cellular infiltration in periarticular soft tissue,
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bone and cartilage damage in Tofa and saline groups; (B) Safranin O-stained joint
sections (10× and 40×). Ta, talus; Ti, tibia; CD, cartilage damage; CI, cell infiltration;
BD, bone damage; (C) Semi-quantitative comparisons of histology scores of all
treatment groups (*, P ≤ 0.05, ANOVA).
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6.3.3 Micro-CT evaluation of joint bone quality
The most severe bone damage was found in the saline group, with extensive
erosion of the entire distal tibia (Figure 6.4A). Tofa-treated animals demonstrated
reduced ankle bone erosion compared to the saline group. Six weeks following
the single dose P-Tofa administration, there was only minor bone erosion. The
quantitative analysis of the hind paw calcaneus trabecular bone (Figure 6.4B) micro-CT data shows that P-Tofa treatment preserved the bone quality as evident in
the morphometric parameters, such as percent bone volume (BV/TV), bone surface density (BS/TV), trabecular separation (Tb.Sp), trabecular number (Tb.N),
bone mineral density (BMD), and trabecular thickness (Tb.Th) with their values
similar to those observed for healthy controls; and significantly better than those
observed for free Tofa-treated and the saline control. When the entire calcaneus
bone was analyzed (Figure 6.4C), the Tofa and saline groups were found with
significantly increased calcaneus tissue volume and calcaneus bone surface, and
significantly decreased calcaneus bone volume percentage, when compared to
the healthy and P-Tofa-treated groups.
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Figure 6.4 Micro-CT analyses of the hind paw of the rats from different treatment
groups. (A) Representative 3-D reconstructed ankle joints from each treatment
group. P-Tofa-treated rats were most similar structurally to the healthy group,
while saline group exhibited extensive bone erosion. Significant bone damage was
also found in the Tofa treated animals; (B) Bone morphometric parameters of the
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red cylinder ROI within calcaneus bone as shown in Figure 6.1; (C) Bone morphometric parameters of the entire calcaneus bone. No significant difference between
the healthy and P-Tofa treated rats was found for all the parameters, indicative of
the potent joint preservation capacity of the single dose P-Tofa treatment. (*, P ≤
0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001)
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6.3.4 Passive targeting and retention of P-Tofa in arthritic joints
Near infrared optical imaging analyses revealed that systemically administered
P-Tofa-IRDye was mainly distributed to arthritic joints (Figure 6.5A). Signals observed at the ear and the base of the tail were attributed to the trauma from ear
tag installation and inflammation associated with immunization. Signal intensity in
the joints gradually decreased from ~1×109 to ~2×108 (p/sec/cm2/sr)/(uW/cm2)
over 12-days. To validate live imaging results, major organs and both hind limbs
were collected at necropsy and imaged ex vivo. The inflamed joints, especially the
hind limb ankle joints, were the major sites of P-Tofa-IRDye distribution with moderate-to-high signal intensity also observed in the liver and kidneys (Figure 6.5B).
The lack of fluorescent signal observation confirmed the absence of P-Tofa in the
other organs. Semi-quantitative analyses of the optical imaging data corroborated
this observation (Figure 6.5C).
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Figure 6.5 Near infrared optical imaging-based analysis of P-Tofa biodistribution.
(A) Representative IVIS images depicting P-Tofa-IRDye biodistribution in AA and
healthy rats after systemic administration. Images obtained 1, 4, 7 and 12 days
after one intravenous injection of P-Tofa-IRDye demonstrate its retention in arthritic joints; (B) Representative ex vivo optical imaging of major organs and limbs
from AA rats at 1, 3 and 7-day post P-Tofa-IRDye administration; (C) Semi-quantitative analyses of P-Tofa-IRDye biodistribution. P-Tofa-IRDye signals were detected mainly in the arthritic joints, liver and kidneys.
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6.3.5 Cellular distribution of P-Tofa
To identify the cell types that sequestered and retained P-Tofa within the joint,
immunohistochemistry staining with a series of cell-specific markers was performed. Numerous P-Tofa-Alexa 647 (red fluorescence) positive cells were found
in synovial tissues where they co-localized with P4HB+ (fibroblast) and CD68+
(monocytes/macrophages) cells, consistent with synoviocyte-mediated subcellular
sequestration of P-Tofa-Alexa 647 (Figure 6.6).
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Figure 6.6 Representative confocal microscopy of anti-CD68 and anti-P4HB antibody stained sections of decalcified ankle joints from AA rates following systemic
administration of P-Tofa-Alexa. Each panel is composed of five subpanels: Antibody signal (green), P-Tofa-Alexa signal (red), DAPI signal (blue), a merged image
at 200× magnification and a merged image at 630× magnification are shown. Colocalization of the red and green colors confirmed the internalization of the P–TofaAlexa by P4HB+ (fibroblast) and CD68+ (monocytes/macrophages) synoviocytes
in the arthritic joints. White arrow points to the sites of colocalization.
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6.3.6 In vitro inhibition of JAK/STAT signaling by P-Tofa and Tofa.
To assess the ability of P-Tofa and Tofa to inhibit JAK/STAT signaling, primary
murine BMM were treated with or without P-Tofa or Tofa for 1 hr or 24 hr, then
challenged with 2 different IL-4 concentrations (0.2 ng/mL and 0.04 ng/mL). qPCR
analysis revealed that, as expected, IL-4 strongly induced expression of alternative
macrophage activation markers Arg1, Ym1/2 and Fizz1, and both Tofa and P-Tofa
pretreatment for 24 hr (Figure 6.7A) or 1 hr (not shown) effectively repressed induction of all three genes. To evaluate if P-Tofa offers sustained anti-inflammatory
activity, cells were pretreated with P-Tofa or Tofa, then washed and cultured for
an additional 72 hr in the absence of the inhibitors, prior to IL-4 challenge. Notably,
under these conditions, P-Tofa retained the ability to repress IL-4 signaling to a
significantly greater extent than free Tofa (Figure 6.7B), suggesting that P-Tofa
provides sustained efficacy via its cellular sequestration and subsequent subcellular Tofa release.
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Figure 6.7 qPCR analyses of expression of Arg1, Ym1/2 and Fizz1 from BMMs
after treatment with IL-4. (A) Expression levels of IL4-induced genes after 24 hr
Tofa or P-Tofa treatment; (B) Expression levels of IL4-induced genes after 24 hr
Tofa or P-Tofa treatment, inhibitor washout and 72 hr additional culture without the
inhibitors. (*, P < 0.05 versus no drug at same level of IL-4; ^, P < 0.05 versus Tofa
at same level of IL-4)
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6.3.7 The impact of Tofa and P-Tofa treatments on serum levels of CXCL 10
To evaluate the effects of Tofa and P-Tofa treatments on systemic inflammatory cytokines, serum levels of CXCL10 were evaluated. As shown in Figure 6.8,
CXCL10 levels were significantly elevated in arthritic rats at day 35 post arthritis
induction, when compared to the healthy controls. A single dose of P-Tofa completely normalized the CXCL10 levels. Daily Tofa treatments also significantly decreased serum CXCL10 levels, though the levels were significantly higher
compared to the P-Tofa group.
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Figure 6.8 Serum CXCL10 levels at days 35 from different groups of rats. (*, P ≤
0.05; ****, P ≤ 0.0001)
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6.3.8 Preliminary toxicity assessment
Under the present dosing level, hematologic profiles of P-Tofa and Tofa treated
animals (Table 6.1) were similar until week 3, when significantly lower total white
blood cells (WBC), neutrophils (NE), eosinophils (EO) and basophils (BA) were
observed in P-Tofa group. A small but significantly lower alkaline phosphatase
(ALP) value was found in the P-Tofa group compared to the Tofa group at necropsy. There were no differences in AST or ALT levels. No histological abnormity
(not shown) was found in major organs from P-Tofa group by the pathologist (SML)
who was blinded to the group arrangement.
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P-Tofa

Tofa
CBC

1 week

2 weeks

3 weeks

1 week

2 weeks

3 weeks

WBC
22.1 ± 6.1 14.9 ± 3.3 10.2 ± 2.7* 24.6 ± 8.0 17.3 ± 5.9 19.1 ± 5.0
(K/µL)
NE
8.3 ± 3.0

5.0 ± 2.0 1.8 ± 1.7* 11.0 ± 3.5 6.4 ± 4.1 7.7 ± 3.3

(K/µL)
LY
11.9 ± 3.0 7.7 ± 1.2

6.3 ± 2.0

12.0 ± 4.0 9.0 ± 3.3 9.9 ± 2.4

0.6 ± 0.3

1.2 ± 0.5

0.8 ± 0.5

0.7 ± 0.4 1.0 ± 0.4 0.6 ± 0.3

0.8 ± 0.6

0.6 ± 0.2 0.1 ± 0.1*

0.7 ± 0.5 0.7 ± 0.4 0.6 ± 0.2

0.3 ± 0.3

0.3 ± 0.1

(K/µL)
MO
(K/µL)
EO
(K/µL)
BA

0.04 ±

(K/µL)

0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.1
0.04*

Liver Function at Necropsy
AST
69.5 ± 2.0

67.6 ± 2.4

76.3 ± 4.7

76.6 ± 2.7

(U/L)
ALT
(U/L)
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ALP
315.3 ± 29.4*

347.3 ± 23.4

(U/L)
Table 6.1 Hematologic profiles and liver function tests with P-Tofa and Tofa treatments. *, P≤0.05, significantly lower than Tofa group
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6.4 Discussion
To test our hypothesis, a HPMA copolymer-based macromolecular prodrug of
Tofacitinib (P-Tofa) was designed, synthesized and evaluated using an adjuvantinduced arthritis rat model. To establish the arthrotropism of P-Tofa according to
our hypothesis, rats with established AA were administered P-Tofa-IRDye and its
biodistribution and tissue-specific retention were evaluated using sequential in vivo
NIR optical imaging. As shown in Figure 6.5A, the IRDye signal mainly localized
in the arthritic limbs. Due to the limited tissue penetration depth of the NIR fluorescent signal [181], the distribution of P-Tofa-IRDye in the major organs and arthritic limbs were imaged ex vivo and analyzed semi-quantitatively using an LICOR small animal imager. The results (Figure 6.5B, 6.5C) confirmed that the inflamed joints in the affected limbs were the major sites of P-Tofa-IRDye localization
with additional distribution sites in the main clearance organs (i.e. liver and kidneys). On a cellular level, immunohistochemistry analysis of the decalcified arthritic joints revealed that the P-Tofa-Alexa was sequestered by fibroblast-like
(P4HB+) and macrophage-like (CD68+) synoviocytes (Figure 6.6), providing direct
evidence of P-Tofa’s targeting to key cell types involved in the joint inflammatory
pathology [182-184].
We hypothesized that the tissue and cellular specificity of systemically administered P-Tofa would lead to a potent and sustained anti-rheumatic effect. Our
original dose equivalent treatment protocol was designed to terminate at day 35
post arthritis induction. The results (Figure 6.2A, 6.2B) established that a single
dose of P-Tofa was effective in ameliorating joint inflammation and improving the
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articular index (AI) scores during this period of time. Having observed this initial
beneficial effect, we further extended the observation period. To maintain dose
equivalence, no additional Tofa was given to the Tofa group. Of importance, the
single dose P-Tofa treated rats continued to show reduced joint inflammation and
articular index score reduction until day 65 post arthritis induction, when signs of a
minor arthritis flare (e.g. a small increase of the arthritis score) was observed. Immediately after the cessation of Tofa treatment, a flare was detected in the Tofa
treated group, which continued to worsen until the experimental endpoint (day 65
post arthritis induction). Tissue histopathology (Figure 6.3A, 6.3B) and micro-CT
(Figure 6.4) analyses of the ankle joints isolated at the end point of the experiment
demonstrated preservation of joint cartilage and subchondral bone integrity in the
animals treated with the single dose P-Tofa. The Tofa-treated animals, in contrast,
showed only moderate bone and cartilage protection when compared to the saline
controls; but exhibited more extensive joint tissue damage compared to the PTofa-treated group.
In vitro cell culture studies were undertaken to compare the efficacy of P-Tofa
and Tofa in inhibition of JAK/STAT signaling. Murine BMM were treated with PTofa or Tofa prior to challenge with IL-4. This cytokine signals via the JAK/STAT6
pathway and induces the expression of markers of alternative macrophage activation, including arginase-1 (Arg1), YM1/2, and Fizz1. qPCR analysis revealed that
IL-4 strongly induced expression of Arg1, Ym1/2 and Fizz1. Tofa treatment for 24
hr or 1 hr effectively repressed induction of all three genes. P-Tofa was equally
effective under these conditions (Figure 6.7A). To assess the relative efficacy of
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P-Tofa or Tofa to produce sustained inhibition of IL-4 induced JAK/STAT signaling,
in a second set of experiments, cells were pretreated with P-Tofa or Tofa, then
washed and cultured for an additional 72 hr in the absence of inhibitors, prior to IL4 challenge. Of importance, under these conditions, the P-Tofa treatment produced sustained inhibition of IL-4 signaling (Figure 6.7B), whereas the Tofa treated
cells became IL-4 responsive by 72 hr. These findings are consistent with sustained release of active drug from the P-Tofa and corroborate well with the in vitro
data (Figure 6.2) showing the sustained release of free Tofa in acidic environments,
present in the synovium of patients with active arthritis and in the subcellular lysosomal compartment in which the macromolecular prodrug is sequestered [175].
To further explore the impact of P-Tofa treatment, we measured the serum levels of CXCL10. In human studies, circulating CXCL10 as well as synovial expression of this chemokine has been shown to be sensitive to Tofa treatment [185] and
it has been implicated as a major contributor to the recruitment and activation of
immune cells involved in the local synovial inflammation. In this study, we found
that CXCL10 levels were significantly elevated in arthritic rats, when compared to
the healthy controls; and a single dose of P-Tofa completely suppressed the elevated serum CXCL10 levels at day 35 post induction of arthritis (Figure 6.8).
Our data attributes this superior and long-lasting therapeutic efficacy of P-Tofa
to its passive targeting to sites of joint inflammation and synoviocyte-mediated local sequestration and sustained Tofa release, which is distinctively different from
Tofa’s pharmacokinetic profile [186]. We did detect alterations in WBC count and
ALP levels in the P-Tofa group in the later stage of the treatment, suggesting P-
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Tofa dosing at this level (130.2 mg/kg, Tofa equivalent, i.v. single dose) may have
reached the upper limit of its therapeutic window, which is 20-times higher than the
Tofa dose (6.2 mg/kg, daily oral gavage) used in a preclinical therapeutic efficacy
study in this particular animal model [187]. Clearly, additional dose escalation and
a more comprehensive toxicity studies are necessary to further advance P-Tofa’s
development. Given its superior and sustained therapeutic efficacy, we postulate
that P-Tofa has significant potential for development as a treatment for RA.
6.5 Conclusion
A single i.v. administration of P-Tofa provided superior and sustained therapeutic efficacy in an adjuvant-induced arthritis rat model, when compared to dose
equivalent daily Tofa treatment. P-Tofa’s significantly widened therapeutic window
holds the promise for enhancing the clinical efficacy of Tofacitinib for the treatment
of RA.
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CHAPTER 7
SUMMARY
7.1 Conclusion
Our laboratory has developed HPMA macromolecular conjugates for early diagnosis and better treatment of the musculoskeletal disorders. The achievement
we obtained proved our concept hypothesis that the macromolecular prodrug delivery system may improve the therapeutic outcome and benefit with the diagnostics targeting. In my PhD program of study, I focused on the investigation of the
impacts of the different macromolecular conjugates’ structure parameters on their
pharmacokinetics, biodistribution and therapeutic efficacy. A series of the conjugates with different molecular weight (MW), drug content, drug-activation mechanism and drug payload were synthesized for this comprehensive investigation.
The labeled conjugates (conjugates with different MW and drug content) were analyzed for their PK/BD profiles in the murine implant loosening model and in vitro
cell culture study. The conjugates with different activation mechanisms were studied for their in vitro releasing kinetics under different condition (different pH values
or with human or rat serum) and in vivo therapeutic efficacy in an adjuvant-induced
arthritis rat model. Our initial model drug for the above studies is a potent glucocorticoid (dexamethasone). To understand if the development of macromolecular
prodrug conjugates may also be beneficial for other drug classes, we designed
and synthesized the HPMA copolymer conjugate (P-Tofa) with a disease-modify-

152

ing-antirheumatic drug (tofacitinib, Tofa). The positive outcome validated our notion that macromolecularization of antirheumatic drug may potneitate the efficacy
of the parent drug and potentially reduce associated systemic toxicities.
7.2 Future plan
Overall, this project has provided deep insights of the HPMA copolymer conjugates’ structure properties’ influence on its efficacy and safety. These information
provides further instruction on the rational design of drug delivery systems for the
clinical management of musculoskeletal conditions. In the future, other polymeric
carrier system and drug classes may also be explored for the improved treatment
of musculoskeletal diseases. Besides passive targeting, different active targeting
moieties, including bone targeting ligands may be introduced to further potentiate
macromolecular prodrug development for better treatment of musculoskeletal diseases.
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